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ABSTRACT OF DISSERTATION

NOVEL MECHANISMS
IN
INFLAMMATORY BOWEL DISEASE

Inflammatory Bowel Diseases, Crohn's Disease and Ulcerative colitis, are
idiopathic chronic conditions with multifactorial determinants. In general, terms,
intestinal inflammation results from abnormal host-microbe interactions. Alterations
in homeostasis involve host genetic factors, environmental cues and unique
luminal microbial niches. We have examined the coordinated expressions of
several molecular targets relevant to the mucosal immune system and i dentified
signature biomarkers of IBD. Qualitative and q uantitative changes in the
composition of microbiota can be related to unique immuno-phenotypes. This in
turn can have more systemic effects that involve energy metabolism. Adiponectin,
an adipose tissue derived adipokine, can restore cellular ATP levels and f ulfills
innate immune functions. We have concluded that IBD might represent a state of
adiponectin resistance relating to chronic inflammation and obesity status.
Lastly we hypothesized that activation of xenobiotic pathway (AHR-aryl
hydrocarbon receptor) can further modulate host immune and metabolic
responses, and t hus contribute to IBD phenotypes. We found that IBD is
associated with robust mucosal, aryl hydrocarbon receptor pathway and related to
proinflammatory cytokine secretion. We conclude that IBD heterogeneity is
reflected through distinct immunophenotypes. Furthermore, environmental cues
that involve the AhR receptor and adipose tissue derived adiponectin are
important regulators of the inflammatory process in IBD.
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Chapter 1
Introduction:
Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic intestinal
disorders known as idiopathic inflammatory bowel diseases (IBD)1. IBD affects
approximately 1.4 million Americans with a peak onset occurring at 15-30 years
of age. The development of CD and UC requires a genetic predisposition, a
dysregulated immune response and an environmental trigger. Candidate genes
include those that regulate innate immunity and epithelial barrier function 2-5
(Figure 1.1). Additional genetic studies have revealed that gene products
involved in the elimination of endogenous small organic cations, drugs and
environmental toxins are linked to CD and UC etiology 6-8 (Figure 1.1).
Lifestyle choices such as diet are thought to contribute to CD and UC by
altering the commensal flora (prebiotics) or promoting obesity related
inflammatory responses 9 (Figure 1.1). Thus, the interactions between genetic
and environmental factors will shape the gut epithelial-innate immune interface
and lead to unique phenotypes in patients with Inflammatory Bowel Diseases.
Current CD therapies are rather broad in action and not particularly focused on
patient characteristics. Understanding the contribution of host and environmental
factors will promote individualized management of this heterogeneous patient
population.
The intestinal barrier is a dynamic multilayered structure that consists of
bacterial biofilm, mucus, epithelium cells and innate immune cells. Dysfunction of
this complex barrier precedes the development of inflammation in patients with
1

Crohn's Disease 10 , as well as established animal models of Inflammatory Bowel
Diseases 11. The intestinal barrier must balance the need for selective
permeability of nutrients with protection form microbial invasion. This daunting
task is accomplished by physical means such as tight junction proteins and
mucus production on one hand and innate immune exclusion mechanisms on the
other hand.
Epithelial cells interact with luminal microbial antigens though specialized
extracellular TLR receptors (toll-like receptors) and intracellular NLR (NOD-like
receptors)12. Downstream signaling through these receptors promotes the
production of antimicrobial peptides (defensins and cryptidins) and microbial
antigen presentation through upregulation of MHC molecules (major
histocompatibility complex). NOD2/Card15 receptor (Nucleotide binding
Oligomerization Domanin2/Caspase activating recruiting Domain 15 receptor)
mutations and defective HBD (human β-defensin) production have been found in
IBD-Crohn's Disease patients13. Polymorphisms of NOD2/Card15 gene are
believed to alter Paneth cell function and thus explain the impairment in
antimicrobial peptides. Mechanistically, NOD2 senses the intracellular bacterial
antigen MDP (muramyl dipeptide) and recruits adaptor proteins with subsequent
activation of the NF-κB pathway. This pathway commonly results in
transcriptional upregulation of proinflammatory genes. Therefore, defective
NOD2 signaling in Inflammatory Bowel Diseases patients seemed, at first
counterintuitive.
Recent studies addressing the role of epithelial NF-κB pathway ,have
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furthered our understanding of the pathophysiology of Inflammatory Bowel
Diseases and patient response to therapy 14. For example, inhibition of NF-kB
signaling, in epithelial cells, was found to result in impaired antimicrobial defense,
enhanced bacterial penetration and a heightened inflammatory response15. The
NF-κB family of transcription factors consists of five members: RelA (p65), c-Rel,
RelB, p50/p105 and p52/p10016. Dimers of these proteins are kept inactive by
interacting with inhibitory proteins of the IκB family. The IκB kinase (IKK) complex
can target the IκB proteins for proteosome-mediated degradation. The canonical
NF-κB signaling pathway requires the regulatory protein IKKγ/NEMO and the
catalytic subunit IKK2 (IKKβ) and leads to RelA nuclear translocation.
Proinflammatory cytokines such as TNF-α and bacterial antigen can trigger this
process.
The alternative pathway involves IKK1 and promotes nuclear accumulation
of p52/RelB dimers. This pathway is important for lymphoid organogenesis and
lymphocyte development. Mice lacking the regulatory protein NEMO, within the
epithelial cells, develop spontaneous colitis at an early age17. Some of the early
events are innate immune system activation and increased epithelial cell
apoptosis. Interestingly intestinal epithelial deletion of IKK2, another component
of the canonical pathway does not lead to this phenotype since the alternative
pathway subunit IKK1 has a compensatory role. The proinflammatory, NF-kB
dependent effects in macrophages and T cells during later stages of colitis, may
overshadow the initial protective role of epithelial NF-kB. In line with these
observations, loss of IKKβ in macrophages and neutrophils was able to attenuate
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chronic colitis in IL10 KO mice18.
Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis)
have a relapsing/remitting pattern. Nevertheless, some patients enjoy prolonged
periods of remission while others have rather continuous activity and poor
response to anti-inflammatory treatment. In light of the opposing role of NF-kB in
acute vs. chronic colitis and epithelial vs. immune cells , it will be important to
determine whether cell specific impairment in this signaling pathway correlates
with clinical course and response to therapy.
An important target of NF-kB/RelA in intestinal epithelial cells is the
polymeric immunoglobulin receptor (pIgR)19. This receptor is responsible for the
active transport of IgA into the gut lumen. The pIgR is synthesized in the
endoplasmic reticulum and delivered to the basolateral membrane of the
intestinal epithelial cell via the Golgi apparatus. At this level, pIgR binds an IgA
dimer and the receptor/ligand complex reaches the apical membrane through the
endosomal compartment. Cleavage of the pIgR extracellular domain releases the
SC (secretory component) with or without IgA dimer. The SC fragment prevents
pIgA (polymeric IgA) degradation and thus enhances humoral immunity.
Moreover, the SC fragment can bind bacterial components such a C. Difficile
toxin A and fimbriae of enterotoxigenic E. coli, and thus limit their pathogenicity2021

.
In addition to a direct effect on epithelial cells, bacteria can induce pro-

inflammatory cytokines and chemokines with subsequent immune cell influx and
increased tissue damage. Free SC can bind IL-8 and scavenge this
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proinflammatory chemokine thus limiting neutrophil infiltration22. Mice lacking
pIgR expression are more susceptible to DSS (dextran sodium sulphate) induced
colitis23. Interestingly these mice have increased IgA production possibly
reflecting a role of pIgR on B cells, or more likely a response to increase bacterial
antigen exposure due to a barrier defect.
The incidence and relevance of pIgR abnormalities in patients with
Inflammatory Bowel Disease has not been established. Moreover, pIgR
polymorphisms have not been associated with increased risk of Crohn's Disease
or Ulcerative Colitis. It is conceivable that variations of pIgR expression reflect
the activity of epithelial NF-kB. Recent in-vitro studies, using the HT-29 human
colon carcinoma line, highlighted the importance of the canonical NF-kB/RelA
component. Upon stimulation with TNFα, these cells respond by quickly
upregulating IL-8 secretion. In contrast, pIgR expression peaked at 24 hrs at the
time when the proinflammatory chemokine IL-8 was downregulated. Given prior
evidence that the SC fragment can bind and neutralize IL-8, we may consider the
late pIgR expression as a defense mechanism needed to terminate the acute
inflammatory response.
The other important observation is that chronic exposure of intestinal
epithelial cells to TNFα maintains high pIgR expression24. Mucosal TNFα is
elevated in patients with Inflammatory Bowel Diseases and thus the abnormal
expression of pIgR could reduce the defense mechanisms of the epithelial
barrier. Furthermore, although TNFα blockade is highly successful in early versus
late disease, the net effect of pIgR expression may lead to epithelial cell immune
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dysfunction and partly explain the less optimal long-term success. It also implies
that knowledge of pIgR expression in mucosal biopsies may help select the best
candidates for anti-TNF therapy in patients with Inflammatory Bowel Diseases.
As outlined above, one of the main functions of polymeric immunoglobulin
receptor is IgA transport across the epithelial cells. IgA plays an important role in
mucosal immunity. IgA has two subclasses, IgA1 and IgA2. IgA2 predominates in
the mucous secretions whereas IgA1 is more abundant in the serum. The dimeric
form of IgA but not the monomer interacts with the pIgR at the basolateral
surface of the epithelial cells. This complex is released at the apical site together
with the secretory component (SC) which retards its digestion in the gut lumen. It
is important to realize that compared to IgG antibodies, IgA does not trigger
complement activation. Given the enormous amount of IgA produced in response
to commensal flora this property prevents an inappropriate innate immune
response to commensals, as seen in patients with Inflammatory Bowel
Diseases25.
Evaluation of patients with inflammatory bowel diseases has demonstrated
an increase in IgG1 antibody subclass26, which is a rather potent activator of the
complement system. Aside from the subsequent induction of pro-inflammatory
cytokines and chemokines, this also reflects a break in tolerance to gut bacteria.
B cell numbers are increased in Inflammatory Bowel Diseases. This may
theoretically compensate for the IgG shift. Nevertheless, J chain expression in
the lamina propria B cells is decreased27 which means less IgA dimers are
formed. Since only polymeric IgA can be transported by pIgR this may translate
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in a luminal IgA deficiency.
Induction of NF-kB downstream of TNFα and toll receptor signals can also
trigger regulatory molecules. The zinc finger protein A20 is part of this negative
feedback regulatory loop. A genome wide association study has identified A20 as
a susceptibility gene for Crohn's Disease. In support of its role in inflammation
control, A20 KO mice develop severe multi-organ inflammation. Specific
deletions of A20 in enterocytes do not result in spontaneous colitis. Nevertheless,
these mice are more susceptible to DSS induced colitis28. Although NF-kB
expression protects enterocytes from apoptotic signals, overactivation in the
absence of A20 may have the opposite effect. The TLR-MyD88-NF-kB signaling
axis may also confer protection form apoptosis. Activation of A20 secondary to
the pro-inflammatory cytokine TNFα may act cooperatively but independent of
the former pathway since the A20/MyD88 double KO mice are more susceptible
to colitis then either single KO strain28. Since enterocyte, specific A20 KO mice
do not develop spontaneous colitis, it is possible that A20 plays a more important
role under pathologic conditions characterized by unchecked proinflammatory
cytokine secretion such as TNFα. On the other hand, transfer of A20 KO bone
marrow into irradiated wild type mice leads to spontaneous colitis that can be
prevented by antibiotic treatment. This suggests that myeloid but not enterocyte
A20 expression prevents inflammatory response against gut flora under normal
conditions.
In chapter 2, I propose that the coordinated expression of NF-kB/RelA,
pIgR, IgA, A20, TNF and IL-8 defines unique phenotypes in patients with
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Inflammatory Bowel Diseases. Figure 1.2 depicts my proposed model whereby
bacterial and pro-inflammatory signals converge on the NF-kB transcriptional hub
to induce epithelial defense mechanisms: anti-apoptotic (RelA), bacterial immune
exclusion (pIgR, IgA), anti-inflammatory (A20), pathogen elimination (TNFα, IL8). Deregulation of these mechanisms in IBD patients can generate a state of
mucosal innate immune deficiency with secondary activation of the acquired
immune arm. Homeostatic functions of the gut epithelial barrier such as IgA,
mucus and antimicrobial peptide secretion require a high level of synthetic
capacity and metabolic activity.
Dysfunction of the protein folding process or insufficient generation of ATP
is likely to promote ER (endoplasmic reticulum) and mitochondrial stress
responses followed by apoptosis and inflammatory mediators. Under these
conditions, restitution of homeostasis requires adequate protein and organelle
turnover. Autophagy is an evolutionary conserved pathway triggered by
ER stress and starvation. In the process of autophagy, cytoplasmic material
(protein, organelles) is engulfed in membrane-coated autophagosomes, which
subsequently fuse with endosomes and lysosomes in order to form
autolysosomes that degrade the ingested material.
The autophagy process is also utilized to remove intracellular bacteria. A
genome wide analysis linked Crohn's Disease to the autophagy gene ATG16L1
(ATG16L1T300A)29. Importantly this gene was associated with impaired clearance
of Salmonella typhimurium. Moreover, studies in mice hypomorphic for ATG16L1
protein expression, as well as ileal biopsies form IBD patients revealed defective
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Paneth cell function30. These cells are found at the bottom of the intestinal crypts
and regulate the bacterial microenvironment by secreting antimicrobial peptides.
Morphological analysis of these Paneth cells also revealed degenerating
mitochondria. Surprisingly these cells expressed higher levels of PPARΎ
(peroxisome proliferator-activated receptor), a master regulator of adipocyte
differentiation as well as adiponectin an adipose tissue anti-inflammatory
adipokine. Intestinal microbiota in obese patients is characterized by an
increased ratio of Firmicutes relative to the Bacteroides species31-32. Interestingly
the abundance of the Bacteroides species in the murine gut is positively
correlated with the expression of α-defensins33. Furthermore, metabolic disorders
associated with low-grade systemic inflammation (type II diabetes, obesity) are
associated with increased gut permeability. Thus, both inflammatory bowel
disease and metabolic disorders appear to share Paneth cell deregulated
function and dysbiosis. Upregulation of adipose tissue signature factors, PPARΎ
and adiponectin may represent a defense mechanism since both exert protective
effects in gut inflammatory states34-35. Therefore, adipose tissue specific factors
can regulate innate immune response in the gut mucosa.
The epidemic of obesity has affected several autoimmune conditions. In
spite of the malabsorbtive nature of Inflammatory Bowel Diseases the percent of
overweight/obese patients is rising36. Moreover, increased incidence of metabolic
syndrome can create a background of low-grade systemic inflammation. A
signature feature of Crohn’s Disease is the development of mesenteric fat
inflammation37. Macroscopically, the fat tissue wraps around the diseased bowel
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segment, and give rise to what is called “creeping fat”. Given the transmural
nature of the inflammation in Inflammatory Bowel Disease, the adipose tissue
inflammation has generally been dismissed as a secondary event. Moreover,
until recently, adipose tissue was primarily viewed as an energy depot.
Emerging data from multiple medical fields clearly demonstrate that
adipocytes and resident adipose tissue macrophages function as bacterial
sensors and thus promote chronic inflammation38. More importantly, adipose
tissue is a source of pro-inflammatory cytokines such as angiotensin, TNF-α, IL6- as well as the anti-inflammatory adipokine, adiponectin and IL-10. The
“creeping fat” that surrounds the bowel can thus become a source of
inflammatory mediators at the expense of the anti-inflammatory adiponectin and
contribute to chronic bowel inflammation. Both macrophages and adipocytes
share regulatory pathways relevant to metabolism and innate immunity 39-40.
Signaling through adiponectin receptors regulates overlapping pathways
responsible for energy balance, insulin sensitivity and macrophage polarization. If
we acknowledge the plasticity of adipose cells that acquire a macrophage like
phenotype during inflammation, the LPS buffering capacity of adiponectin and
the availability of endogenous TLR4 ligands in the fat depot, then metabolism
and inflammation can no longer be considered as separate processes.
Previous studies addressing the role of adiponectin in experimental colitis
yielded controversial results 41-42. In chapter 3 I address the effects of
adiponectin overexpression in a model of DSS and the therapeutic benefit of a
plant homologue43. Adiponectin (AdipoQ) is unique among adipokines, because
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its circulating levels are inversely related to the adipose mass44-45. The human
adiponectin gene contains a signal sequence, a collagen like domain, and a
globular domain similar to the complement factor C1q. Biological effects of
adiponectin depend upon the formation of multimeric complexes. The basic unit
is a trimer, which can associate through disulfide bonds to generate hexamers
and dodecamers referred to as low, medium and high molecular weight
adiponectin (LMW, MMW, HMW) respectively46.
Cleavage of the adiponectin molecule by leukocyte esterase can release
the globular part, which retains biological activity. It is important to distinguish
between these isoforms since they may have opposing effects on inflammation.
Both pro- and anti-inflammatory effects have been described for all forms of
adiponectin47-50. This is in part explained by the experimental conditions and cell
type, although LPS contamination is another important factor51. Recent studies
suggest that HMW weight adiponectin is the main anti-inflammatory moiety52. In
vitro experiments have shown that globular adiponectin induces NF-kB and proinflammatory cytokines, but prolonged exposure blocks further activation. In
contrast, HMW adiponectin can quickly prevent NF-kB activation53.
Studies in Crohn’s disease patients and experimental colitis have reported
total adiponectin level rather than HMW. Adiponectin production is regulated at
transcriptional and post-translational levels. During adipogenesis, several
transcription factors, including PPARγ, bind its promoter to upregulate mRNA
expression54. Following translation, adiponectin undergoes hydroxylation of
proline and lysine residues as well as glycosylation of hydroxylysines. These
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processes along with formation of disulfide bonds are required for HMW complex
assembly55-56. Furthermore, these bonds are essential for adiponectin secretion.
An endoplasmic reticulum (ER) chaperone protein, ERp44, retains
adiponectin within the cell. Ero1-Lα, another chaperone, competes with
adiponectin for binding to ERp4457. Ultimately, the balance between the two ER
proteins may regulate the amount of secreted adiponectin. The volume of
adipose tissue influences plasma levels of adiponectin. Obese patients have
lower adiponectin levels. Weight loss through caloric restriction, exercise or
bariatric surgery increases adiponectin or at least the ratio of HMW to total
adiponectin58-61. Similar to findings in Crohn's Disease, obesity is associated with
adipocyte ER stress, which leads to decreased adiponectin exocytosis and
hypoadiponectemia62. In-vivo and in-vitro studies suggest that the visceral rather
than the subcutaneous fat is the main source of adiponectin. Importantly, the size
of adipocytes correlates with the amount of secreted protein. Large, insulin
insensitive adipocytes have lower secretion61,63.
Two main adiponectin receptors with homology to G protein-coupled
receptors have been identified. These receptors have distinct tissue specificities
within the body and have different affinities to the various forms of adiponectin
(mono or multimers)64. Adiponectin binds to the extracellular COOH terminus of
adiponectin receptors (AdipoR1 / AdipoR2) and recruits the adapter APPL1
(adaptor protein containing PH domain) which in turn activates AMPK (AMPactivated protein kinase)65. APPL1 is rather promiscuous and interacts with at
least 14 proteins that modulate apoptosis66, endosomal localization of proteins67,
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and chromatin remodeling. Recruitment of APPL1 by adiponectin receptors
induces AMPK (5'-AMP activated protein kinase) phosphorylation. This process
requires the upstream LKB1 kinase and to a lesser extent Ca2+/ calmodulin
dependent protein kinase kinase (CaMKK)68. Activation of AMPK by CaMKK can
provide a direct link between ER stress and autophagy. Decreased cellular ATP
during starvation or states of mitochondrial dysfunction can also activate AMPK.
Under these circumstances, the upregulation of adiponectin in Paneth cells
carrying the ATG16L1T300A mutation may be interpreted as a trigger for
autophagy.
APPL1 and AMPK also modulate PI3K/AKT (phosphoinositide-3-kinase
and protein kinase B) and mTOR (mammalian target of rapamycin), which
function as regulatory hubs in both metabolic and immune processes. Signaling
cascades that polarize T cell and macrophage responses incorporate these
molecules69. Therefore, adiponectin can regulate both the acquired and innate
arms of the immune responses. AICAR (5 aminoimidazole-4-carboxamide
ribose) a non-specific AMPK activator ameliorates experimental autoimmune
encephalitis70-71, a model dependent on Th1/Th17 effector cells.
Analysis of both murine and human macrophage cell lines found high
basal expression AMPK, predominantly the α1 isoform72. The cytokine milieu can
regulate its expression in these cells. Anti-inflammatory cytokines IL-10 and
TGFβ upregulate while TLR4 agonist, LPS downregulate its expression.
Inhibition of macrophage AMPK amplifies the TNFα and IL-6 response to LPS.
Mechanistically the AMPK enhances Akt activity, which in turn phosphorylates
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and inactivates its substrate GSK3-β. This Akt target promotes Th1 cytokine
expression. In addition, GSK3-β can negatively regulate CREB (cyclic AMP
responsive element binding protein) expression, a known activator of IL10
production in macrophages. Moreover, AMPK prevents IkB degradation and
indirectly the NF-kB translocation to the nucleus. Overall, the activity of AMPK in
macrophages appears to promote an M2 (alternatively activated) antiinflammatory phenotype.
Previous unpublished data from my laboratory indicate decreased mucosal
adiponectin receptor (AdipoR1/R2) expression in subsets of patients with
moderate to severe Crohn’s disease. It is currently unknown whether this is a
global event, or is restricted to certain cell types. Peroxisome proliferatoractivated receptor gamma(PPARγ) can increase adiponectin sensitivity by
upregulating its receptors73, while the opposite may be true for the proinflammatory adipokine, angiotensin. Thus, PPARγ can enhance macrophage
response to adiponectin.
Intestinal epithelial cells produce angiotensin converting enzyme (ACE)
that mediates the conversion of angiotensinogen (produced by adipocytes and
macrophages) into the biologically active angiotensin I (ANG-I)74. Angiotensin
has pro-inflammatory and profibrotic activity and can negatively regulate
adiponectin and adiponectin receptors. A significant number of Crohn's Disease
patients develop fibrotic strictures and require surgical intervention. Adiponectin
can prevent fibrosis by reducing the TGFβ signaling75 in an AMPK and PPARα
dependent manner. Angiotensin can downregulate AMPK /PPARα and enhance
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TGFβ expression76. Therefore, the relative balance of adiponectin and
angiotensin could modulate TGFβ dependent epithelial-to-mesenchimal transition
and determine the Inflammatory Bowel Disease behavior.
Despite normal/reduced ACE activity in the serum, ACE levels are
increased in the mucosa of Crohn’s patients and correlate with disease activity77.
Since macrophages and adipocytes produce angiotensinogen (AGT)78-80,
epithelial ACE may promote inflammation within the gut and mesenteric fat.
Medications that block angiotensin increase adiponectin, adiponectin receptor
expression, and ameliorate experimental colitis, thus supporting these
observations81. The relative antagonism of adiponectin and angiotensin as well
as competition for PI3/AKT and p38MAPK pathways could theoretically alter
epithelial cell cycle, and sensing of bacteria82. This in turn would influence NF-kB
dependent targets such as pIgR (polymeric IgA receptor), tight junction proteins,
and inflammatory cytokines.
Adiponectin induces mucosal IL-10 production (unpublished data) and
activates p38MAPK (p38 mitogen-activated protein kinase). The p38MAPK/IL10/STAT3 axis inhibits inflammation-induced ER stress response mechanism83.
STAT3 expression positively correlates with AdipoR2 expression in Crohn’s
Disease patients, and adiponectin reduces ER stress response in DSS colitis.
Thus, adiponectin may activate p38MAPK/IL-10/STAT3 axis during states of
inflammation. AMPK activation downstream of adiponectin receptor could
dampen the Th1/Th17 immune response during acute and chronic phases of
colitis while promoting the M2 type macrophages (Figure 1.3)
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Environmental factors can affect adipose tissue volume and distribution.
Prior studies in our laboratory identified a link between Aryl hydrocarbon pathway
(AhR), abnormal adipocyte metabolism and inflammation84. Specifically, AhR
agonist PCB77 promoted adipose tissue Th1 cytokine expression, activation of
the renin angiotensin system and decrease adiponectin. Cigarette smoke
contains a mixture of AhR agonists and is associated with complicated forms of
Crohn's Disease. It is well known that the gene/environment interplay contributes
to the pathogenesis of chronic disease states such as IBD.
Perhaps one of the best examples of this type of gene/environment
interplay is that of the pregnane X receptor (PXR) signaling pathway. The
association between IBD and the PXR pathway was first identified following gene
expression profiling of inflamed tissues obtained from patients with Ulcerative
Colitis and Crohn Disease. Increasing evidence supports the idea that activation
of the AhR by environmental factors may similarly impact the severity of IBD.
Like the PXR, the AhR regulates both xenobiotic metabolism and the
inflammatory response. For example, exposure to environmental agents such as
PCB 77 and cigarette smoke activates the AhR leading to the upregulation of
phase I (CYP1A1 and CYP1B1), and phase II (UGT1A1 and GSTA1) of the
xenobiotic metabolism.
The AhR is a basic helix-loop helix transcription factor that in its latent
form, resides in the cytosol as a complex comprised of a dimer of heat shock
protein of 90 kDa (HSP90), an immunophilin (ARA9) and p2385. The presence of
an AhR agonist triggers translocation of the AhR into the nucleus where it
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dimerizes with its DNA binding partner, aryl hydrocarbon nuclear translocator
(ARNT) and binds specific DNA recognition sites, the xenobiotic response
elements (XRE) and thus either upregulates or downregulates a battery of genes.
Prototypical AhR target genes most commonly studied are those involved in
xenobiotic metabolism, in particular, CYP1A1 and CYP1B. These genes encode
enzymes that are highly induced following exposure to AHR agonists86. AhR
translocation to the nucleus can also trigger an auto-regulatory negative
feedback thorough aryl hydrocarbon receptor repressor (AHRR).
Proinflammatory metabolites of arahidonic acid (i.e. lipoxin A4) and
tryptophan were recently identified as relatively potent AhR agonists87-89. This
indicates that the AhR signaling pathway plays a role in the regulation of the
inflammatory responses. For example, 6-formylindolo [3, 2-b] carbazole (FICZ) a
tryptophan derivative, generated by UV light exposure, is a potent AhR inducer
and can be detected in human urine. Interestingly, several gram positive and
negative bacteria present in the human gut can also process tryptophan, and
thus generate AhR ligands in the form of indoles. On the other hand, indolenegative bacteria produce oxygenases that interfere with indole signaling. Taken
together these observations suggest that the relative distribution of indole
positive/negative bacteria can modulate intestinal epithelial and immune cells
function.
Dietary habits can influence the amount of tryptophan intake and alter the
composition of bacterial biofilm. AhR agonists that are typically used in research
to induce the AhR signaling pathway are environmental contaminants, such as
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dioxin (TCDD or 2, 3, 7, 8-Tetrachlorodibenzo-p-Dioxin) and other
polychlorinated hydrocarbons such as PCBs. In addition, studies have shown
that polyaromatic hydrocarbons present in cigarette smoke act as potent AhR
agonists. In fact, the AhR has been recently identified as a major regulator of
responses elicited by exposure to cigarette smoke. The aryl hydrocarbon
receptor is strongly expressed in the gut, particularly in small bowel intestinal
epithelial cells. Furthermore, either oral or intraperitoneal administration of AhR
agonists resulted in rapid induction of CYP1A1 expression in the intestinal crypts.
Thus, a number of ubiquitous xenobiotics, such as PCBs and cigarette smoke,
are capable of activating the AhR signaling pathways in cells of the
gastrointestinal mucosa.
The canonical AhR pathway activates nuclear enzymes important for endoand xenobiotic metabolism (CYP450). AhR can also interact with NF-kB subunits
(non-canonical pathway) and modulate inflammation90. Several mechanisms
have been proposed regarding the AhR /NF-kB interaction91: 1) direct binding
NF-kB to CYP ( cytochrome) genes; 2) transcriptional repression involving
factors such as PPAR, RXR and LXR; 3) post-transcriptional regulation of CYP
activity through heme-oxygenase .
The differentiation of naïve CD4 T cells into Th1 is important for controlling
intracellular bacterial infections while Th2 cells initiate antibody responses
against extracellular pathogens. Aryl hydrocarbon receptor plays an important
role in the development of both Th memory and Th effector cells (Figure 1.4) and
by extension in the development of chronic inflammatory conditions like IBD92-94.
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The CD4+ Th17 cells are defined by a high AhR expression and a combination of
IL17A, IL17F and IL22 cytokines95. Activation of Th17 cells by FICZ (short acting
AhR agonist) augment these cytokines production and induce the expression of
AhR battery genes. Supporting the relationship between AhR and Th17 cells is
the fact that Th17 cells from AhR KO mice cannot produce IL22, implying that
AhR activation is required for IL-22 production in this T cell subset. In addition,
since macrophages and dendritic cells induce IL22 through IL-23 release
indicates that IL23 functions downstream of the aryl hydrocarbon receptor (AhR).
Recent studies have also demonstrated that AhR can bind the IL17
promoter and this interaction is negatively regulated by the nuclear receptor liver
X receptor (LXR) 96. Th17 development is impaired in AhR KO mice. On the other
hand, Th17 polarizing cytokines, TGFβ and IL6 induce AhR expression in these
cells97. Increased AhR expression was correlated with lower signal transducer
and activator of transcription 1 (STAT1) levels. This may suggest that AhR can
antagonize the negative effect of IFNΎ (STAT1 activator) on Th17 cells
development97.
Intestinal epithelial cells (IEC) can also express IL22 that promotes release
of antimicrobial peptides. There is no evidence that AhR ligands are driving IEC
IL22 secretion but given the role of NF-kB in Paneth cells and NF-kB – AhR
interaction, the latter may modulate the innate immune function of the
gastrointestinal mucosa. In favor of this interaction is the fact that IL22
expression is upregulated in the gut mucosa of Crohn's Disease patients and
plays an important role in experimental colitis as well.
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Short acting AhR ligands, such as FICZ promote inflammation. In contrast,
the long acting agonist TCDD has been associated with immunosupression.
Several mechanisms may be involved in this process: 1) direct effect on T cells;
2) modulation of antigen presenting cell (APC) function; 3) toxic effect on bone
marrow stem cells. In a mouse model of IBD (TNBS induced colitis), TCDD
induced forkhead box P3 (FoxP3) expression and decreased the severity of
colitis98. A similar mechanism has been proposed in a model of experimental
autoimmune encephalitis (EAE) 95. Dendritic cells (DC) can polarize naïve T cells
toward the Treg phenotype by expressing IL10 and decreasing the availability of
tryptophan. AhR is required to induce indoleamine 2, 3-dioxygenase (IDO)
expression in DC. This enzyme catabolizes tryptophan into metabolites like
kynurenine (Kyn) which promotes inducible Treg (iTreg) development. Taken
together, the AhR pathway can regulate the Th17/Treg balance.
Although animal studies using TCDD indicate that AhR ameliorates
inflammation this may not apply to human conditions such as IBD (excluding
accidental exposure). The naturally occurring ligands are rapidly metabolized,
whereas synthetic, long acting compounds such as TCDD persist and will
accumulate in the body. Therefore, experiments in AhR KO and heterozygote
mice will allow us to determine the overall effects of endogenous ligands on the
development of Inflammatory Bowel Diseases.
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Figure 1.1 Inflammatory Bowel Diseases paradigm
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Figure 1.2 Epithelial Innate Immune Molecular Targets
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Figure 1.3 Role of Adiponectin in Inflammatory Bowel Disease
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Figure 1.4 Aryl hydrocarbon receptor and T cell polarization

Copyright @ Razvan I Arsenescu

24

Chapter Two
The content of Chapter 2 has been published in the Journal of Mucosal
Immunology. Permission to reproduce this material has been obtained from the
Nature Publishing Group.

SIGNATURE BIOMARKERS IN CROHN ’S DISEASE: TOWARD A
MOLECULAR CLASSIFICATION

Synopsis
In an effort to develop a molecular classification scheme for Crohn ’ s
disease (CD), mucosal biopsies from 69 CD patients and 28 normal controls
were analyzed for expression of the RelA subunit of nuclear factor (NF)- kB, A20
(a negative regulator of NF- kB), polymeric immunoglobulin receptor (pIgR),
tumor necrosis factor (TNF), and interleukin (IL)-8. Principal component analysis
was used to classify individuals into three subsets based on patterns of
biomarker expression. Set 1 included normal subjects and CD patients with mild
disease and good responses to therapy, thus defining “normal” biomarker
expression. CD patients in set 2, characterized by low expression of all five
biomarkers, had moderate to severe disease and poor responses to
immunosuppressive and anti-TNF therapy. Patients in set 3, characterized by low
expression of RelA, A20, and pIgR, normal TNF and elevated IL-8, had acute
inflammation that responded well to therapy. Classification of CD patients by
these biomarkers may predict disease behavior and responses to therapy.
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Introduction
Crohn’s disease (CD) is a chronic disorder characterized by patchy
transmural inflammation of the small and / or large bowel, thought to result from
an inappropriate inflammatory response to normal components of the intestinal
microbiota in genetically predisposed individuals. 1 – 3 Progress has been made in
characterizing the effector cells and molecules that comprise the inflammatory
response, and current biological therapies are targeted toward neutralizing these
effectors. 4 – 7 However, recent evidence suggests that the primary defect in CD
may actually be a defective innate immune response within the intestinal
mucosa. 8,9 There is general agreement that molecular biomarkers for CD are
needed to improve diagnosis and guide therapies.10 The aim of this study was to
identify a set of biomarkers representative of the innate immune response in the
gut mucosa, which could be used to classify CD patients into molecular phenotypic subsets predictive of disease behavior and responses to therapy.
The association of nuclear factor (NF- kB) signaling with induction of proinflammatory cytokines has led to the hypothesis that excessive activation of NFkB is central to the pathogenesis of CD.11,12 Recent findings, however, have
suggested that activation of NF-kB may be crucial for regulation of intestinal
inflammation and maintenance of epithelial barrier function. 13–15 Thus
“physiological” inflammation induced by RelA signaling may be important for
maintaining epithelial homeostasis in the gut, and reduced expression of RelA
could contribute to the “innate immunodeficiency” seen in CD.
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NF-kB induces expression of A20, an ubiquitin-modifying enzyme that
negatively regulates the NF-kB activation pathway. 16,17 Mice genetically deficient
in A20 are hypersensitive to tumor necrosis factor (TNF)- and Toll-like receptor
(TLR) induced NF- kB activation, and develop severe intestinal inflammation. 18
We hypothesized that reduced expression of A20 in the intestinal mucosa could
therefore be a risk factor for CD.
Secretory antibodies of the IgA class (SIgA) form the first line of antigenspecific immune protection at mucosal surfaces and promote homeostasis
between the intestinal epithelium and the commensal microbiota. 19, 20 Transport
of IgA across intestinal epithelial cells into the gut lumen is mediated by the
polymeric immunoglobulin receptor (pIgR). 21, 22 Following transport, the
extracellular domain of pIgR is cleaved to form secretory component (SC), which
remains associated with SIgA and confers additional innate immune functions. 23
,24

Targeted deletion of the Pigr gene in mice causes elevated serum IgA,

increased mucosal permeability, and increased susceptibility to experimental
colitis. 25 – 27 Expression of pIgR in intestinal epithelial cell is upregulated by TNF and
TLR signaling via activation of NF- kB. 21, 22 We hypothesized that diminished
expression of pIgR in the intestinal mucosa could lead to increased inflammatory
responses to the commensal microbiota.
The pro-inflammatory cytokine TNF is associated with mucosal
inflammation in CD, and therapies designed to neutralize TNF activity have
shown promise in a subset of CD patients who are refractory to conventional
therapies. 6, 28 TNF also has protective roles in innate immunity, including
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induction of NOD2 and pIgR expression, epithelial restitution, and control of
potentially pathogenic luminal bacteria. 29 – 32 We hypothesized that although
optimal expression of TNF in the intestinal mucosa may promote physiological
inflammation, reduced TNF could lead to defective innate immunity.
Interleukin (IL)-8 is a potent chemoattractant for neutrophils, the major
component of the cellular infiltrate in acute inflammation. 33 Although neutrophils
contribute to mucosal inflammation through the release of soluble mediators,
they also play an important role in removal of bacteria and foreign debris that
could otherwise promote a granulomatous response by mucosal macrophages. 8,
9

Accordingly, we investigated IL-8 as a potential biomarker for acute

inflammation in CD patients.
Given the heterogeneous clinical presentation in CD, we anticipated that
no single biomarker would accurately predict disease behavior. We utilized a
multifactorial approach to develop a molecular classification scheme, based on
expression levels of RelA, A20, pIgR, TNF, and IL-8 in the intestinal mucosa of
CD patients and normal controls.

Materials and Methods
Study subjects. Peripheral blood and mucosal biopsies were obtained from
individuals undergoing colonoscopy at the University of Kentucky Medical
Center, after institutional review board approval and written informed consent.
For CD patients, the indication for colonoscopy was either to evaluate disease
exacerbation or to screen for dysplasia and colorectal cancer. Diagnosis of CD
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was based on clinical, radiological, and endoscopic criteria according to the
Montreal classification, 41 supported by histopathological findings. Active disease
was defined by a Harvey–Bradshaw index 40 >4 or endoscopic evidence of active
inflammation. Control subjects aged 50 years or older underwent screening
colonoscopies for colon cancer in accordance with current guidelines. Control
subjects under 50 years of age underwent colonoscopy for evaluation of
constipation or chronic abdominal pain. Individuals were classified as “normal”
when endoscopic, radiologic, and pathologic evaluation of randomly obtained
biopsies revealed no disease of the small or large bowel.

Analysis of mRNA levels in colonic and ileal mucosa. Biopsied tissue was
immediately immersed in an RNA-stabilizing solution (RNAlater; Qiagen,
Valencia, CA) and stored at − 80 °C. Total RNAwas purified using the Qiagen
RNeasy Protect mini kit (Qiagen) according to the manufacturer’s directions.
RNA was reverse-transcribed to generate cDNA templates using the TaqMan
Gold RT-PCR kit (Applied Biosystems, Foster City, CA). Specific mRNA levels
were quantified by real-time reverse transcription PCR, using the ABI Prism 7700
Sequence Detection System (Applied Biosystems) as previously reported. 32 The
level of 2-microglobulin mRNA, which did not vary between normal subjects and
CD patients, was used to normalize mRNA levels for test genes according to the
following formula: (2 -(C test − C 2-microglobulin)) × 100 %.
Preliminary studies indicated that gene expression did not vary significantly in
different regions of the large bowel (cecum, transverse colon, and rectum) within
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each individual. Accordingly, biopsies of non-inflamed mucosa from different
regions of the colon were pooled into a single sample for mRNA analyses.

Measurement of serum IgA and immunolocalization of IgA and pIgR. Serum IgA
levels were measured using a commercial ELISA kit for human IgA (Bethyl
Laboratories, Montgomery, TX). Mucosal biopsies were immediately fixed in
formalin and then embedded in paraffin. The sections (5 – 7 μm) were mounted
on glass slides, deparaffinized, rehydrated, quenched with 3 % H2O2, and treated
for 10minwith a citricacidbased antigen-unmasking solution (Vector Laboratories,
Burlingame, CA). Sections were blocked with normal goat serum (1 % in
phosphate-buffered saline) and incubated overnight at 4°C with primary
antibodies: monoclonal mouse anti-human IgA, (Santa Cruz Biotechnology,
Santa Cruz, CA; catalog no. sc66185) (diluted 1:50) and polyclonal rabbit antihuman SC (the extracellular domain of pIgR) 45 (diluted 1:200). Sections were
washed and incubated for 1 h with a mixture of Cy2-conjugated goat anti-mouse
IgG and Cy3-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA; catalog nos. 115225-146 and 111-165-144).
Sections were counterstained with 4', 6-diamidino-2-phenylindole dihydrochloride
(Molecular Probes Invitrogen, Eugene, OR) to visualize nuclei and mounted with
VECTASHIELD medium (Vector Laboratories). Stained sections were imaged
with an Olympus BX51 microscope, using a ×20 objective. ImagePro software
was used to generate the composite images.
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Analysis of NOD2 mutations. Genomic DNA was extracted from whole blood
using the AquaPure Genomic DNA Isolation kit (BioRad, Hercules, CA). The
R702W, G908R, and 1007fsinsC polymorphisms in the NOD2 gene were
detected by restriction fragment length polymorphism analysis of PCR-amplified
DNA, as described. 42

Statistical analyses. All statistical analyses were performed using StatView
software (SAS Institute, Cary, NC). Because biomarker expression did not follow
normal Poisson distributions, non-parametric statistical analyses were used for
all comparisons. Mann – Whitney analysis was used to test for significant
differences among groups of individuals. Paired sign analysis was used to
compare differences in gene expression in paired biopsies within individuals.
Spearman correlation analysis was used to test for correlations in mRNA levels
among different biomarkers. PCA 36 was used to reduce the five variables
(biomarkers) into two PCs. Expression levels for biomarkers from non-inflamed
colon or ileum mucosa from all subjects in the cohort (normal controls and CD
patients) were included in the PCA. The goodness-of-fit of the two PCs for the
colon and ileum data sets was tested by χ² analysis. To assign individual scores
for PC1 and PC2, the expression level for each of the five biomarkers for each
individual was first normalized to the mean for that biomarker for all subjects in
the cohort. Individual scores for PC1 and PC2 were then calculated as the sum
of the normalized value for each biomarker times the weight for that biomarker.
Individuals were classified into subsets according to their scores for PC1 and
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PC2. The χ² analysis was used to test the effects of clinical parameters and
medications at time of biopsy on distribution of CD patients into phenotypic
subsets.

Results
Biomarker expression in CD patients and normal controls
Mucosal biopsies from the colon and /or terminal ileum were obtained at
colonoscopy from 69 CD patients and 28 normal controls (Figure 2.1 a). Based
on visual inspection and histology, tissues were classified as inflamed or noninflamed. To test the hypothesis that the innate immune response is inherently
dysregulated in CD patients, we compared mRNA levels in the colon and ileum
for five potential biomarkers in non-inflamed tissue from CD patients and healthy
controls (Figure 2.1 b and c). Levels of RelA, A20, and TNF mRNA were
significantly lower in non-inflamed colon mucosa of CD patients than in normal
controls. Expression of pIgR in colon mucosa was highly heterogeneous in
normal controls and was not significantly different from CD patients. However,
the observation that many CD patients had low pIgR expression suggested that
this biomarker might be used to identify a subset of CD patients with deficient
pIgR-mediated IgA transport. IL-8 expression was extremely low in the majority
of normal controls and CD patients. However, elevated IL-8 expression in some
CD patients suggested that this biomarker could be useful in a multifactorial
analysis of gene expression. There were no significant differences in expression
in the ileum mucosa between normal controls and CD patients for any of the five
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biomarkers, suggesting that dysregulated expression of RelA, A20, and TNF may
be a unique feature of the large bowel in CD. To determine whether expression
of these biomarkers varies between the colon and ileum, paired biopsies (within
the same individual) were analyzed from 19 normal controls (Figure 2.2 a) and
22 CD patients (Figure 2.2 b). Expression of pIgR was higher in the colon than in
the ileum of both normal controls and CD patients, likely due to enhanced TLR
signaling from greater numbers of commensal bacteria. 34 We have previously
reported that pIgR expression is significantly higher in the colon than in the ileum
in mice and is reduced in mice with deficient TLR signaling. 35 Expression of RelA
was slightly but significantly higher in the colon than in the ileum of CD patients,
but not of normal controls. No differences in expression of A20, TNF, or IL-8
were observed between the colon and ileum of either normal controls or CD
patients. We conclude that regional differences in gene expression between the
colon and ileum do not account for the observation that dysregulated expression
of RelA, A20, and TNF in CD patients was restricted to the large bowel.
To test the hypothesis that local inflammation influenced biomarker expression,
we analyzed paired biopsies of non-inflamed and inflamed colon mucosa from 17
CD patients (Figure 2.3 a). Remarkably, there were no significant differences in
mRNA levels for any of the five biomarkers, suggesting that the observed
dysregulation of gene expression in CD patients was an inherent condition of the
colon mucosa, and not secondary to local inflammation. Because access to the
ileum during colonoscopy was limited to the terminal 10 – 20 cm, we were only
able to obtain a single biopsy of the ileum mucosa per individual. Accordingly,
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each CD patient was classified as having either non-inflamed or inflamed ileum,
even though regional differences in inflammation could have existed in other
parts of the small bowel. Interestingly, no differences in the expression of RelA,
A20, pIgR, or TNF were observed among different CD patients with or without
ileal inflammation (Figure 2.3 b). However, expression of IL-8 was significantly
elevated in mucosa of CD patients with visible inflammation in the terminal ileum,
suggesting that this gene may be a biomarker for acute ileal disease.

Multifactorial analysis of five biomarkers defines molecular phenotypic subsets in
CD
The heterogeneous patterns of gene expression in both normal controls and CD
patients suggested that a multifactorial scheme might be more robust than
individual biomarkers for classifying molecular phenotypes. Principal component
analysis (PCA) is a statistical approach that is used to reduce the number of variables in a complex data set and to classify relationships between variables. 36 A
recent study utilized PCA to identify a subset of IBD patients with significant
abnormalities in the composition of the colonic microbiota. 37 We used PCA to
classify our study cohort (including both normal controls and CD patients) into
molecular phenotypic subsets based on expression of RelA, A20, pIgR, TNF, and
IL-8 mRNA in non-inflamed intestinal mucosa. The first step in this analysis was
to examine patterns of correlated expression among the five potential biomarkers
(Figure 2.4 a). In the colon, highly significant correlations were observed among
the expression levels of RelA, A20, pIgR, and TNF, consistent with the function
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of NF- kB in inducing transcription of the A20, pIgR, and TNF genes. Expression
of TNF but not RelA was positively correlated with IL-8, suggesting that TNF may
promote IL-8 gene transcription through a RelAindependent mechanism. In the
ileum, A20 expression was positively correlated with RelA and TNF, but RelA
and TNF were not correlated with each other. In contrast to the colon, IL-8
expression was positively correlated with pIgR but not TNF.
Principal component analysis was used to reduce the five variables to two factors
or principal components (PCs) (Figure 2.4 b). The χ² analysis demonstrated that
most of the variability in the data set could be described by PC1 and PC2 (P <
0.0001 for the colon and P = 0.0255 for the ileum). On the basis of colon gene
expression, PC1 was strongly weighted toward RelA, A20, and pIgR, with an
intermediate weight for TNF and a negative weight for IL-8 (see Factor tables in
Figure 2.4 b). PC2 was strongly weighted toward TNF and IL-8, with a low weight
for RelA and negative weights for A20 and pIgR. For ileum gene expression, PC1
was strongly weighted toward RelA, A20, pIgR, and TNF and weakly weighted
toward IL-8. PC2 was strongly weighted toward IL-8, weakly weighted toward
pIgR and TNF, and negatively weighted toward RelA and A20. Each normal
control and CD patient was assigned a score for PC1 and PC2 based on the sum
of weighted expression levels for all five biomarkers (see Methods). Scatter plots
of the scores for PC1 vs. PC2 demonstrated that individuals could be classified
into three subsets based on colon or ileum gene expression (Figure 2.4 c). Set 1
is defined as individuals with a high score for PC1 and a low score for PC2, set 2
is defined as individuals with low scores for both PC1 and PC2, and set 3 is
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defined as individuals with a high score for PC2. On the basis of colon gene
expression, 81 % of normal controls were classified into set 1, with8% in set 2
and 11 % in set 3 ( Figure 2.4 d). On the basis of ileum gene expression, the
percentages of normal controls in sets 1, 2, and 3 were 57, 38, and 5 %,
respectively. These findings suggested that high scores for PC1 and low scores
for PC2, particularly for the colon, define a “normal” molecular phenotype. In
contrast, 42 % of CD patients were classified in set 1 based on colon gene
expression, with 45 % in set 2 and 13 % in set 3. On the basis of ileum gene
expression, the percentages of CD patients in sets 1, 2, and 3 were 33, 45, and
22 % , respectively.
Patterns of colon gene expression differed significantly for CD patients classified
into the three molecular phenotypic subsets (Figure 2.5). Individuals in set 2 had
significantly reduced expression of RelA, A20, pIgR, and TNF compared to
individuals in set 1 (the “normal” phenotype). Individuals in set 3 had significantly
reduced expression of RelA, A20, and pIgR, normal expression of TNF, and
elevated expression of IL-8. On the basis of these findings, we propose that CD
patients in set 2 have an inherent deficiency in innate immunity in the colon
mucosa. CD patients in set 3 had selected features of innate immunodeficiency
(reduced RelA, A20, and pIgR), but elevated IL-8 expression in this group was
suggestive of acute inflammation. Classification of individuals based on ileum
gene expression was less informative than for the colon. CD patients in ileum set
2 had some evidence of innate immunodeficiency (reduced levels of RelA and
A20), but expression of pIgR and TNF was normal. CD patients in ileum set 3
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had elevated IL-8 expression, but no evidence of innate immunodeficiency. We
conclude that RelA, A20, pIgR, TNF, and IL-8 are potentially useful biomarkers
for classification of CD patients into molecular phenotypic subsets based on gene
expression in non-inflamed colon mucosa. Accordingly, we compared clinical
findings in CD patients distributed into the three colon subsets.

Aberrant localization of pIgR and SIgA in a subset of CD patients
Deficient pIgR expression in mice has been associated with reduced transport of
SIgA into the colon lumen and elevation of serum IgA. 25,26We observed that
serum IgA levels tended to be lower in CD patients than in normal controls
(Figure 2.6 a), but given the overall heterogeneity, this difference did not achieve
statistical significance. However, serum IgA levels were significantly elevated in
CD patients in set 2 (Figure 2.6 b), who had decreased expression of pIgR in the
colonic mucosa (Figure 2.5 a). Serum IgA levels also appeared to be elevated in
CD patients in set 3, although due to the relatively small number of individuals in
set 3 the difference from set 1 was not statistically significant. To examine
whether reduced pIgR-mediated transport of IgA contributed to the elevation in
serum IgA, we compared the localization of pIgR and IgA in colonic biopsies from
a normal individual in set 1 and from a CD patient in set 2 (Figure 2. 6 c). In the
normal colon mucosa, pIgR and IgA were colocalized at the basolateral surface,
within the cytoplasm, and at the apical surface of epithelial cells, consistent with
normal transport of IgA. In the lamina propria, IgA was observed in association
with plasma cells, but no pIgR was detected. In contrast, staining for pIgR was
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markedly reduced in epithelial cells of non-inflamed mucosa from the set 2 CD
patient, and there was reduced evidence of transepithelial transport of IgA. In
addition, more IgA was observed in the lamina propria, compared with the normal
control. A punctuate border of colocalized pIgR / SC and IgA at the apical surface
of the epithelium most likely represented SIgA bound to the mucus layer. In the
inflamed mucosa from the same CD patient, dense colocalization of IgA and
pIgR / SC in the lamina propria was suggestive of deposition of SIgA along the
basement membrane. Leakage of excess IgA (either free or bound to SC) from
the lamina propria into the systemic circulation could account in part for the
elevated levels of serum IgA in set 2 CD patients.

Correlations between molecular phenotypes and clinical outcomes of CD patients
A review of the clinical histories of CD patients in this cohort indicated that, in
general, patients in set 1 tended to have mild disease and good responses to
therapy; patients in set 2 had moderate to severe disease and poor responses to
immunosuppressive and anti-TNF therapy; and patients in set 3 had acute
disease that responded promptly and durably to therapy.
Although young age at diagnosis of CD has been reported to be associated with
more severe disease,38 we observed no differences among the three subsets in
age at diagnosis (Mann – Whitney test, P>0.05). We did find that set 3 patients
tended to be more recently diagnosed, independent of the age at diagnosis
(Figure 2.7). Set 3 patients also had elevated serum C-reactive protein, a marker
of acute inflammation in CD10 (Figure 2.7). These data suggest that some CD
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patients may present initially with acute inflammation (set 3), but the inherent
innate immunodeficiency characterized by reduced expression of RelA, A20, and
pIgR (and likely other genes) results in a failure to resolve the underlying trigger
of inflammation. Over time, these patients may progress from acute to chronic
inflammation, characteristic of set 2.
Recent evidence suggests that inflammatory mediators produced by visceral
adipose tissue may promote intestinal inflammation in CD. 39 However, we observed
no differences in body mass index among molecular phenotypic subsets,
indicating that excess body fat did not influence expression of the biomarkers we
analyzed. There were also no significant differences among subsets in Harvey–
Bradshaw index of disease activity 40 at the time of colonoscopy, suggesting that
subjective evaluation of disease activity at one point in time may not be
informative with respect to the underlying molecular pathogenesis of the disease.
Other clinical characteristics that did not affect distribution of CD patients into
molecular phenotypic subsets included gender, smoking behavior, and disease
location (colon vs. ileum, or both) (Table 2.1).
Crohn’s disease patients with an inflammatory or stricturing phenotype (Montreal
classification41) were evenly distributed among the three molecular phenotypic
subsets (Table 2.1). In contrast, patients with penetrating disease were
significantly biased toward set 3 and away from set 2 (P = 0.019). Given that only
three patients in our cohort had penetrating disease, these data must be
interpreted with caution. However, the possibility that the combination of innate
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immunodeficiency and acute inflammation that characterizes set 3 may
predispose patients to penetrating disease deserves further investigation.
Only one patient in our cohort (classified in set 1) was homozygous for the
L1007fsinsC polymorphism in the NOD2 gene, which confers increased risk for
CD 42 (Table 2.1). Several additional patients were heterozygous for other NOD2
polymorphism - but these did not affect their distribution among the molecular
phenotypic subsets. These findings suggest that the abnormalities in innate
immunity identified by our classification scheme are unrelated to NOD2
polymorphisms.
We next investigated whether the medications that CD patients were receiving at
the time of biopsy affected their patients among the three subsets (Table 2.2).
We conclude that the observed abnormalities in mucosal gene expression in sets
2 and 3 reflected an underlying pathology characteristic of each individual, and
did not result from acute effects of medications they were receiving at the time of
biopsy. This finding does not rule out the possibility that medications received
earlier in the course of the disease may have had long-term effects on mucosal
gene expression.

DISCUSSION
Signature biomarkers for CD
Here we describe a molecular classification scheme, based on expression of
RelA, A20, pIgR, TNF, and IL-8 in the colon mucosa, which identifies unique
phenotypic subsets of CD patients. Several findings support the concept that
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these are molecular phenotypes. The χ2 analysis revealed no significant effect of
any medication on distribution of CD “signature biomarkers” for CD. First,
biomarker expression appeared to be an inherent characteristic of each CD
patient, and was not affected by local variations in tissue inflammation or current
medications. Second, these biomarkers identified a potential state of innate
immunodeficiency in the majority of CD patients in our cohort, accompanied by
chronic (set 2) or acute (set 3) mucosal inflammation. Third, classification of CD
patients into these molecular phenotypic subsets was predictive of disease
behavior and responses to therapy. Our findings provide strong support for
prospective studies of this molecular classification scheme in a larger population
of CD patients.

A model for dysregulated innate immunity in CD
The pathology of CD arises from an imbalanced immune response to exogenous
and endogenous molecular cues. Traditionally, CD has been viewed as an
exaggerated inflammatory response to microbial antigens caused by a
dysregulated adaptive immune response. However, recent evidence suggests
that the primary defect in CD may actually be a deficient innate immune
response in the intestinal mucosa, resulting in inadequate clearance of bacteria
and other foreign material from the lamina propria and generation of a chronic
inflammatory state. 8,9 The intestinal epithelium is a crucial player in maintaining
this balance, going beyond the simple role of a physical barrier to orchestrate the
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physiological inflammatory response and the innate immune response to dietary
and microbial antigens.
We propose that expression of RelA, A20, pIgR, TNF, and IL-8 may be useful for
assessing innate immune function in the colon mucosa. A model describing the
activities of these molecules in normal and diseased mucosa is presented in
Figure 2.8. In healthy mucosa, cross talk between epithelial cells and
constituents of the commensal microbiota is essential for maintaining normal
expression of the RelA subunit of NF- kB. Constitutive low-level activation and
nuclear translocation of NF- kB result in physiological inflammation,
characterized by high expression of pIgR and other proteins involved in epithelial
polarity and function, as well as moderate expression of TNF, IL-8, and other
effectors of innate immunity. Coordinate expression of negative regulatory
molecules such as A20 protects epithelial cells from excessive activation and
nuclear translocation of NF- kB. IgA produced by plasma cells in the lamina
propria is transported across the epithelial layer by pIgR, thus promoting
intracellular and extracellular neutralization of microbes and their products and
regulating immune effector molecules such as IL-8. 23, 24, 43 Reduced expression
of RelA in the colon mucosa of some CD patients may compromise the ability of
epithelial cells to mount a physiological inflammatory response to the commensal
microbiota. Reduced expression of pIgR could inhibit normal transport of IgA,
resulting in diminished regulation of microbial products and IL-8, compromised
barrier function, and deposition of SIgA complexes in the lamina propria. Low
mucosal expression of RelA may also predispose CD patients to periodic flares
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of pathological inflammation, due to reduced expression of negative regulators
such as A20, diminished anti-inflammatory activity of SIgA, increased access of
microbial antigens to the lamina propria, activation of macrophages and
generation of an adaptive immune response.

Protective roles for NF- kB / RelA in the intestinal epithelium
Association of NF- kB signaling with induction of pro-inflammatory cytokines in T
cells and inflammatory cells such as macrophages and neutrophils has
supported the use of therapies designed to inhibit activation of NF- kB. 1. When
considering these therapeutic approaches, it should be kept in mind that
physiological NF- kB signaling is important for maintenance of intestinal
homeostasis. It has recently been reported that selective inhibition of NF- kB
activation in intestinal epithelial cells, by targeted deletion of genes encoding
subunits of the IkB-kinase complex, actually increases the susceptibility of mice
to experimental colitis. 13,14 A critical role of the RelA subunit of NF-kB in intestinal
homeostasis was highlighted by the recent report that mice with a targeted
deletion of Rela in intestinal epithelial cells exhibited reduced expression of prorestitution genes, elevated epithelial apoptosis and proliferation, and increased
susceptibility to chemically induced colitis.15 Our data suggest that reduced
expression of the RelA subunit of NF- kB in the gut mucosa, with concomitant
downregulation of key target genes, may be a contributing factor for the
development of CD in humans.
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NF-kB signaling in the intestine is kept under tight control by a complex network
of negative regulatory molecules, many of which are target genes of NF-kB. 17 To
represent this group of negative regulators in our panel of biomarkers, we
analyzed expression of A20, a ubiquitin-editing enzyme that downregulates NFkB signaling initiated by pro-inflammatory cytokines and TLRs. 44 A20 null mice
have been shown to develop severe intestinal inflammation, 18 suggesting that
A20 and other negative regulators may fulfill the role of a “brake” and set the
threshold for NF- kB activation. We consistently observed down-regulation of
mucosal A20 expression in CD patients, which may hamper their ability to
regulate pathological NF-kB activation induced by acute inflammatory responses.
Significantly, we found that A20 levels did not increase in inflamed regions of the
colon in CD patients (Figure 2.3). Paradoxically, CD may be characterized both
by a defect in physiological NF- kB signaling and by a reduced capacity to
regulate pathological NF-kB signaling.

Compartmentalization of IgA in the intestinal epithelium is crucial for barrier
function
Compartmentalization of IgA antibodies in the gut enhances barrier function by
allowing a local antigen-specific response to commensal microorganisms without
stimulating potentially inflammatory systemic immune responses. 20 We observed
that reduction of pIgR expression in some CD patients (set 2) led to reduced
transport of IgA and accumulation of dense membranous deposits of SIgA
(Figure 2.6). Elevated serum IgA levels in this group of CD patients could have
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resulted from leakage of IgA from the lamina propria into the systemic circulation,
which has been reported in pIgR-deficient mice. 25,26 Elevated serum IgA could
also result from deficient epithelial barrier function and access of the commensal
microbiota to the lamina propria, resulting in a loss of tolerance and a systemic
immune response to microbial antigens.

Potential applications of a molecular classification scheme for diagnosis and
management of CD
The results of this study support the concept of developing a molecular
classification scheme for CD based on patterns of gene expression in the colon
mucosa. Using this scheme, we classified a cohort of CD patients into three
molecular phenotypic subsets that were generally predictive of clinical findings
and responses to therapy. It will be important to validate this model in a larger
cohort and to evaluate the utility of additional biomarkers. Molecular classification
of CD patients at the time of diagnosis may be helpful in targeting specific
therapies. For example, patients classified in set 3, with evidence of acute
inflammation, may respond better to TNF blockers and other biological therapies
than would patients classified in set 2, who exhibited subnormal expression of
TNF in the colon mucosa. This classification system may also be useful for
monitoring the course of the disease and modifying therapy over time. We found
that recently diagnosed patients were more likely to be classified in set 3,
whereas patients with longstanding disease were more likely to be classified in
set 1 or set 2 (Figure 2.7), suggesting that patients may undergo transition over
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time into different subsets. Our finding of reduced mucosal expression of RelA in
both set 2 and set 3, as well as the need for physiological NF- kB activation to
maintain epithelial barrier function, suggests that the application of therapies
designed to inhibit NF-kB activation should be used with caution.
Acknowledgments: This research was supported by grants from the Investigatorsponsored study program of AstraZeneca, the National Institutes of Health, the
Kentucky Science & Engineering Foundation, the Crohn ’ s & Colitis Foundation
of America, the Eli and Edythe Broad Foundation, and UCB SA

Table Legends
Table 2. 1 Comparison of clinical characteristics and molecular phenotypes of
CD patients. Abbreviation: CD, Crohn’s disease. The χ² analysis tested the
hypothesis that CD patients displaying each of the listed clinical characteristics
would be distributed among the molecular phenotypic subsets in the same
proportions in which the entire cohort of CD patients was distributed, i.e., set 1:
set 2: set 3; 22:24:7 (see Figure 2.4 d).

Table 2.2. Effects of medications at the time of biopsy on molecular phenotypes
of CD patients Abbreviation: CD, Crohn’s disease. The χ² analysis tested the
hypothesis that CD patients receiving each of the listed medications would be
evenly distributed among the molecular phenotypic subsets in the same
proportions in which the entire cohort of CD patients was distributed, i.e., set 1:
set 2: set 3; 22:24:7 (see Figure 2. 4 d). Medications: 5-ASA: mesalamine;
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immunosuppressants: azathioprine, 6-mercaptopurine, methotrexate; steroids:
budesonide, prednisone; anti-TNF: Remicade (inﬂiximab), Humira (adalimumab).
Some patients were receiving more than one medication at the time of biopsy.

Figure legends
Figure 2.1 Biomarker expressions in CD patients and normal controls. Patient
characteristics (a) and gene expression in non-inflamed colon (b) and ileum (c)
mucosa were compared between CD patients and normal controls. mRNA levels
were measured by RT-qPCR and normalized to β2-microglobulin mRNA. Data
are displayed as histograms to illustrate the heterogeneity in expression of
individual biomarkers. Dashed lines indicate median expression levels for each
group. Significant differences among groups were tested by Mann – Whitney
non-parametric analysis; P-values are listed for each comparison of normal
controls vs. CD patients. CD, Crohn’s disease; RT-qPCR, real-time quantitative
PCR.

Figure 2.2 Comparison of gene expression in colon and ileum. Paired biopsies
were obtained from non-inflamed mucosa of the colon and ileum for 19 normal
controls (a) and 22 CD patients (b). mRNA levels were measured by RT-qPCR
and normalized to 2-microglobulin mRNA. Dashed lines indicate the difference in
median expression levels between colon and ileum for each gene. Significant
differences among groups were tested by paired sign non-parametric analysis; P-
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values are listed for each comparison of colon vs. ileum. CD, Crohn’ s disease;
RT-qPCR, real-time quantitative PCR

Figure 2.3 Effects of local inflammation on gene expression. mRNA levels were
measured by RT-qPCR and normalized to 2-microglobulin mRNA.
(a) Paired biopsies were obtained from non-inflamed and inflamed colon mucosa
from 17 CD patients. Dashed lines indicate the difference in median expression
levels between non-inflamed and inflamed mucosa for each gene. Significant
differences among groups were tested by paired sign non-parametric analysis; Pvalues are listed for paired comparisons between inflamed vs. non-inflamed
colon mucosae. (b) Histograms of gene expression in inflamed or non-inflamed
ileum mucosae from different individuals. Because of limited access to the ileum
during colonoscopy, a single biopsy from the terminal ileum for each CD patient
was classified as either inflamed or non-inflamed, and paired biopsies could not
be collected. Significant differences among groups were tested by Mann –
Whitney non-parametric analysis; P-values are listed for each comparison of
individuals with inflamed vs. non-inflamed ileum mucosa. CD, Crohn’s disease;
RT-qPCR, real-time quantitative PCR.

Figure 2. 4 Multifactorial analysis of gene expression patterns. (a) Nonparametric Spearman correlation analysis of gene expression data from Figure
2.1 Correlation coefficients (r) and P-values are listed for each comparison.
Statistically significant correlations (P< 0.05) are shaded. (b) Factor analysis of
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NF-kB, RelA, A20, pIgR, TNF, and IL-8 mRNA levels in non-inflamed colon and
ileum mucosa, including both normal controls and CD patients. Weighted factors
are listed for principal components (PCs) 1 and 2 for each gene. (c) Classification
of individuals into molecular phenotypic subsets. Scores for PC1 and PC2 were
calculated for each individual based on the sum of weighted expression levels for
all five biomarkers (see Methods). Set 1 comprises individuals with a high PC1
score and low PC2 score. Set 2 comprises individuals with low scores for both
PC1 and PC2. Set 3 comprises individuals with high scores for PC2. The table
lists the distribution of normal controls and CD patients among colon and ileum
subsets. The scatter plots represent the scores for PC1 and PC2 for each
individual; open circle =normal control; filled circle =CD patient. (d) Distribution of
individuals into molecular phenotypic subsets based on scores for PC1 and PC2.
CD, Crohn ’ s disease; IL, interleukin; NF- kB, nuclear factor- kB; PC, principal
component; pIgR, polymeric immunoglobulin receptor; TNF tumor necrosis
factor.

Figure 2.5 Comparison of individual biomarker expression in CD patients
grouped by molecular phenotype. CD patients were classified in sets 1 – 3 by
principal component analysis, as described in Figure 2.4. mRNA levels in colon
(a) and ileum (b) mucosa were measured by RT-qPCR and normalized to 2microglobulin mRNA. Gene expression levels for sets 1, 2, and 3 were compared
by non-parametric Mann – Whitney analysis and are expressed as median +
median absolute deviation. Asterisks indicate that gene expression in set 2 or 3
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is different from that in set 1 (P< 0.05). CD, Crohn’s disease; RT-qPCR, real-time
quantitative PCR.

Figure 2.6 Serum IgA levels and localization of pIgR and IgA in colonic mucosa
of normal controls and CD patients. (a) Histograms of serum IgA levels in normal
controls and CD patients. Dashed lines indicate median levels for each group.
Differences in serum IgA levels for normal controls vs. CD patients were tested
by Mann – Whitney non-parametric analysis. (b) Comparison of serum IgA in CD
patients classified in sets 1 – 3 by principal component analysis, as described in
Figure 2.4. Serum IgA levels in sets 1, 2, and 3 were compared by nonparametric Mann – Whitney analysis and are expressed as median + median
absolute deviation. An asterisk indicates that gene expression in set 2 or 3 is
different from that in set 1 (p < 0.05). (c) Localization of pIgR / SC and IgA in
colonic mucosa by immunofluorescence. Representative images are shown from
a normal subject (representing set 1) or matched biopsies from visibly inflamed
and non-inflamed regions of the colon from a CD patient with low pIgR mRNA
expression (representing set 2). Red staining indicates binding of antibody to
human SC and green staining indicates binding of antibody to human IgA. All
samples were counterstained with DAPI to visualize nuclei. Stained tissue
sections were imaged with a × 20 objective; the bottom panels are enlargements
of the designated regions from merged images. CD, Crohn’s disease; DAPI, 4 ',
6-diamidino-2-phenylindole dihydrochloride; E, epithelium; LP, lamina propria;
pIgR, polymeric immunoglobulin receptor; SC, secretory component.
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Figure 2.7 Clinical characteristics of CD patients classified in sets 1 – 3 based on
colon gene expression. Disease duration is defined as the time from initial CD
diagnosis to when the mucosal biopsy was collected / each individual. Values for
sets 1, 2, and 3 were compared by non-parametric Mann – Whitney analysis and
are expressed as median + median absolute deviation. P-values indicate
significant differences between CD patients in set 2 and set 3. No significant
differences were observed between set 1 and sets 2 or 3. CD= Crohn’s disease.

Figure 2. 8 Model for inflammation due to dysregulated mucosal gene expression
in Crohn’s disease. (a) (1) In normal mucosa, bacterial – epithelial cross talk
upregulates expression and activation of NF- kB (RelA) and expression of
downstream targets (A20, pIgR, and TNF). Modulation of these responses by
A20 and other negative regulators limits the “physiologic inflammation.” (2) IgA
secreted by lamina propria plasma cells binds to pIgR on the basolateral surface
of epithelial cells and is transported to the apical surface. (3) During transport,
SIgA facilitates clearance of bacterial antigens and inflammatory chemokines. (4)
SIgA promotes immune barrier function at the luminal surface. (b) (1) Defective
expression of NF- kB and downstream genes by epithelial cells in CD. (2)
Abnormal deposits of SIgA in the lamina propria. (3) Failure of IgA-mediated
clearance of antigens and IL-8 due to defective epithelial transport. (4) Reduced
SIgA at the luminal surface results in diminished barrier function. (5) Excess SIgA
in the lamina propria enters the systemic circulation. (6) Chronic inflammation
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with increased IL-8 and influx of neutrophils and macrophages. CD, Crohn’ s
disease; IL, interleukin; NF- kB, nuclear factor- kB; pIgR, polymeric
immunoglobulin receptor; SIgA, secretory antibodies of the IgA class; TNF, tumor
necrosis factor.
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Table 2.1 Comparison of clinical characteristics and molecular phenotypes of CD
patients
Number of subjects
Set 1
Factor

Observed

Set 2

Set 3

Expecte
d

Observed

Expected

Observed

Expected

2

P

Gender
Male

7

8.7

9

9.5

5

7.0

2.153

0.341

Female

15

13.3

15

14.5

2

4.2

1.413

0.493

Smoking behavior
Smoker

7

6.6

8

7.2

1

2.1

0.684

0.710

Non-smoker

15

13.7

13

14.9

5

4.4

0.471

0.790

Disease location
Ileum only

7

5.0

4

5.4

1

1.6

1.413

0.493

Colon only

4

4.6

5

5.0

2

1.5

0.276

0.871

Ileum+colon

11

12.0

14

13.1

4

3.8

0.154

0.926

Disease behavior
Inflammation
only

10

8.3

6

9.1

4

2.6

2.078

0.354

Stricturing

11

11.6

14

12.7

3

3.7

0.303

0.860

Penetrating

1

1.2

0

1.4

2

0.4

7.898

0.019

NOD2 polymorphisms
+/-

4

2.1

0

2.3

1

0.7

4.223

0.121

+/-

0

0.4

1

0.5

0

0.1

1.208

0.547

1

0.4

0

0.5

0

0.1

1.409

0.494

R702W
G908R

L1007fsinsC
+/+
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Table 2.2 Effects of medications at the time of biopsy on molecular phenotypes
of CD patients
Number of subjects
Set 1
Medication

Set 2

Set 3

Observed

Expected

Observed

Expected

Observed

Expected

No

10

13.3

17

14.5

5

4.2

1.388

0.500

Yes

12

8.7

7

9.5

2

2.8

2.114

0.347

No

14

12.0

14

13.1

1

3.8

2.469

0.291

Yes

8

10.0

10

10.9

6

3.2

2.983

0.225

No

13

14.9

18

16.3

5

4.8

0.442

0.802

Yes

9

7.1

6

7.7

2

2.2

0.937

0.626

No

16

17.8

21

19.5

6

5.7

0.330

0.848

Yes

6

4.2

3

4.5

1

1.3

1.417

0.492

2

P

5-ASA

Immuno suppressants

Steroids

Anti-TNF
biologics
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Figure 2.1 Biomarker expressions in CD patients and normal controls.
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Figure 2.2 Comparison of gene expression in colon and ileum.
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Figure 2.3 Effects of local inflammation on gene expression
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Figure 2.4 Multifactorial analysis of gene expression patterns

58

Figure 2.5 Comparison of individual biomarker expression in CD patients
grouped by molecular phenotype
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Figure 2.6 Serum IgA levels and localization of pIgR and IgA in colonic mucosa
of normal controls and CD patients
60

Figure 2.7 Clinical characteristics of CD patients classified in sets 1 – 3 based on
colon gene expression
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Figure 2.8 Model for inflammation due to dysregulated mucosal gene expression
in Crohn’s disease

Copyright @ Nature Publishing Group
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Chapter Three
The content of Chapter 3 has been published in the Journal of Digestive
Diseases and Sciences. Permission to reproduce this material has been obtained
from the Springer Publishing House.

ADIPONECTIN AND PLANT DERIVED-MAMMALIAN ADIPONECTIN HOMOLOG EXERT A PROTECTIVE EFFECT IN MURINE COLITIS

Synopsis
Background: Hypoadiponectinemia has been associated with states of chronic
inflammation in humans. Mesenteric fat hypertrophy and low adiponectin have
been described in patients with Crohn’s disease. We investigated whether
adiponectin and the plant-derived homolog - Osmotin - are beneficial in a murine
model of colitis.
Methods: C57BL/6 mice were injected (i.v.) with an adenoviral construct
encoding the full-length murine adiponectin gene (AN+DSS) or a reporter - LacZ
(Ctr and V+DSS groups) prior to DSS colitis protocol. In another experiment,
mice with DSS colitis received either Osmotin (Osm+DSS) or saline (DSS) via
osmotic pumps. Disease progression and severity were evaluated using body
weight, stool consistency, rectal bleeding, colon lengths, and histology. In vitro
experiments were carried out in bone marrow derived dendritic cells.
Results: Mice overexpressing adiponectin had lower expression of
proinflammatory cytokines (TNF, IL-1β), adipokines (angiotensin, osteopontin),
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and cellular stress and apoptosis markers. These mice had higher levels of IL-10,
alternative macrophage marker – arginase 1 and leukoprotease inhibitor. The
plant adiponectin homolog Osmotin similarly improved colitis outcome and
induced robust IL-10 secretion. LPS induced a state of adiponectin resistance in
dendritic cells that was reversed by treatment with PPARγ agonist and retinoic
acid.
Conclusion: Adiponectin exerted protective effects during murine DSS colitis. It
had a broad activity that encompassed cytokines, chemotactic factors as well as
processes that assure cell viability during stressful conditions. Reducing
adiponectin resistance or using plant derived adiponectin homologs may become
therapeutic options in IBD.

Introduction
Inflammatory Bowel Diseases, Crohn’s Disease and Ulcerative colitis are
chronic relapsing conditions that result from an inappropriate response to gut
microbiota 99. Crohn’s disease patients develop transmural inflammation of the
gastrointestinal tract, which may lead to complications such as strictures and
perforations. Recent advances in metabolic and cardiovascular diseases have
led to a paradigm shift in which adipose tissue has been upgraded from an
energy depot to a source of immunomodulatory cytokines (adipokines). In his
original description of the disease, Burril Crohn directed the attention toward the
characteristic mesenteric fat change100. Accumulation of mesenteric fat appears
to be specific for Crohn’s disease, and occurs from the onset of disease37. Fat
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wrapping has been defined as fat hypertrophy extending from the mesenteric
attachment with > 50% coverage of the intestinal surface101. It occurs in both the
small and large bowel, and correlates with transmural inflammation, ulceration,
stricture formation, increased mesenteric wall thickness, and decreased internal
bowel diameter101. Fat wrapping and mural thickening is associated with
mucosal ulceration in 86% 102 and with strictures in 46% of patients 102.
Importantly, it was noted in 100% of patients undergoing resection, and
correlated with the degree of acute and chronic inflammation103.
Functional pattern recognition receptors (PPRs) have been recently
identified in nonimmune cells like adipocytes, as well. Therefore, by expressing
functional cell membrane PPRs like Nucleotide-binding oligomerization domain
containing 2 (NOD2), cluster of differentiation 14 (CD14), toll-like receptors
(TLR2, TLR4, and TLR5) the adipose tissue can also, respond to bacterial wall
products, developing a proinflammatory phenotype104. When we consider the fact
that preadipocytes may differentiate towards the macrophage line and that NOD2
mutation is strongly associated with Crohn’s disease, the adipose tissue
becomes a dynamic player for the disease phenotype. In addition, TLR signaling
leads to decreased expression of the adipose tissue anti-inflammatory adipokine
– adiponectin and lowers its receptors104. It also promotes free fatty acid
accumulation that act as an endogenous TLR4 ligand. Therefore, a vicious cycle
is established that potentially induces a state of hypoadiponectemia and/or
adiponectin resistance. Considering that adiponectin can bind and neutralize
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lipopolysaccharide (LPS) the hypoadiponectemia can lead to secondary
activation of the immune system105.
Angiotensinogen is the precursor of the inflammatory adipokine
angiotensin and is secreted by the adipocytes. Angiotensinogen negatively
regulates adiponectin expression106. In addition, epithelial cells and macrophages
produce angiotensinogen-converting enzyme (ACE) that catalyze the conversion
of the pro-inflammatory peptide - angiotensin 107-108. In turn, angiotensin
promotes Th1 type cytokine production and development of colitis 81. Hence,
another vicious inflammatory circle may occur between adipocytes, epithelial
cells and macrophages. In contrast, agonists of peroxisome proliferator-activated
receptor gamma (PPARγ), a common signature marker in the early
developmental phase of both adipocytes and macrophages induce both
adiponectin and adiponectin receptors109. Rosiglitazone, a PPARγ agonist has
been shown to be beneficial in human Inflammatory Bowel Disease and
experimental colitis110.
Obesity, a state of hypoadiponectemia, is associated with more severe
Crohn’s disease and atherosclerosis. Interestingly, defective macrophage
function and autophagy has been described in both conditions111-112. Autophagyrelated protein 16 (ATG16L1) upregulate adiponectin expression in Paneth cells
and mutations in this gene is associated with Crohn’s disease29. Mice ATG16L1
hypomorphic have defective autophagy processes, possibly because of impaired
anti-microbial peptides production29. Due to the fact that gut microbiota
suppresses the epithelial expression of fasting-induced adipose factor (FIAF),
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that promotes triglyceride accumulation, the bacterial-epithelial crosstalk could
alter adipose mass, and by extension the balance of adipokines and cytokines113.
Current studies regarding the adiponectin role in colitis are
controversial. We hereby, show that adiponectin treatment ameliorates colitis in a
murine DSS model. Furthermore, we demonstrate that adiponectin alters the
balance of key regulatory cytokines and adipokines relevant for both
experimental and human disease. In addition, we propose that a plant derived
adiponectin homolog may be considered as a viable and accessible IBD
treatment.

Materials and Methods
Materials
99.9% pure Dextran Sulfate Sodium (DSS) was purchased from MP Biomedicals,
Santa Ana, CA. Adiponectin adenovirus was a generous gift from Dr Jerry
Olefsky, Loyola University, CA. Osmotin was purified from salt adapted cultured
tobacco cells as described [36]. No contaminants were detected in the osmotin
preparation by a combination of 2DGE and mass spectrometric methods. The
endotoxin content was <0.03 EU/mg protein.

DSS - induced colitis and sample collection
Male, 3 months old C57BL/6 (Jackson Laboratory, n = 6 mice/group) were
randomly divided into 3 groups, as described in treatment protocols below. All
groups of mice were housed in a pathogen-free environment with free access to
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food and water. Colitis was induced by administration of 3.5% (wt/vol) DSS in
water for a week, followed by 3 days of water only. Body weight, stool
consistency and rectal bleeding were monitored daily. On day ten, mice were
euthanized with ketamine/xylazine (100/10 mg/kg i.p.) for blood and tissue
harvest. The colons were removed and perfused with phosphate-buffered saline
(PBS - pH 7.4), and measured. Half of each colon was fixed in RNAlater
(Qiagen), and stored at -20°C. The other half was made in a “swiss roll”, cut and
fixed in 10% buffered formalin (Sigma Chemical). The Animal Care and Use
Committee at the University of Kentucky approved all procedures.

Adiponectin overexpression
The control (Ctr) and V+DSS mice were intravenously (i.v.) injected with
adenovirus suspension (2x 108 pfu, 0.1ml per mouse) carrying the reporter gene
LacZ (β-Galactosidase). Mice in the AN+DSS were intravenously injected with
an adenovirus suspension (2X108 plaque forming units (pfu), 0.1ml per mouse)
carrying the murine adiponectin gene. The Ctr group had only water while the
V+DSS and AN+DSS groups were fed DSS in the drinking water. All groups
received the above i.v treatments 3 days prior to DSS colitis protocol. Blood
samples were taken at the end of the study to measure the adiponectin plasma
level using an enzyme- linked immunosorbent assay (ELISA- mouse cytokine
panel – LINCOplex, Millipore, Billerica, MA)

Treatment with the mammalian adiponectin homolog - osmotin
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To assess the role of an adiponectin homolog in the treatment of IBD, male, 3
months old C57BL/6 (Jackson Laboratory, n = 8 mice/group) were divided into
control (Ctr) group that received phosphate buffered saline only, a DSS group
that received saline and DSS (DSS), and a group that received osmotin (73
ug/Kg/h) and DSS (OSM+DSS). All treatments (saline & Osmotin) were delivered
for 2 weeks using Alzet mini-osmotic pumps (Durect Corp., Cupertino, CA). The
pumps were implanted subcutaneously in the suprascapular area under sterile
conditions. They ensured constant delivery of drug during the experiment. During
the last 10 days, all mice except the Ctr group, received DSS in the drinking
water for 7 days, followed by water for 3 days. Mice were euthanized with
ketamine/xylazine and examined for macro and histopathological abnormalities.
The osmotic pumps were removed and the residual volume was determined.
Blood was collected for Adiponectin and IL10 measurements by ELISA (mouse
cytokine panel – LINCOplex, Millipore, Billerica, MA).

Histologic analyses and Proliferating Cell Nuclear Antigen (PCNA) assay
Formalin fixed colons were embedded in paraffin. From these, serial sections (5 7 μm) were stained with hematoxylin and eosin. A pathologist blinded to the
group allocation assessed the severity of colitis as described elsewhere114. The
sections were deparaffinized and treated with Antigen Retrieval Solution (DAKO,
Carpinteria, CA) followed by incubation in 0.3% H2O2-methanol for 10 min, and
wash. Sections were incubated in normal blocking serum for 90 min followed by
overnight incubation in primary antibody, NCL-PCNA (1:200) (Novocastra, Leica

69

Microsystems) at 4°C. The biotinilated secondary antibody ([Elite ABC kit,
Vector) was then applied for 2 hours. The slides were counterstained with Methyl
Green (DAKO). Images were taken with an Olympus BX51 microscope (Olympus
America, Inc.) at 20x magnification.

Analysis of mRNA gene expression levels in mouse colonic tissue
Total RNA was purified using MagnaPure Compact RNA Isolation Kit (Roche)
from whole colon tissue and cDNA was obtained using Transcription High Fidelity
cDNA Synthesis Kit (Roche). Specific mRNA levels were quantified by real time
reverse transcription-polymerase chain reaction (RT-PCR), using the IQ iCycler
(Bio-Rad), and SYBR Green qPCR Supermix (Bio-Rad). Primers were designed
using the Primer 3 software (SourceForge) and the sequences are shown in
Table 1. The target genes mRNA level were normalized to reference gene
according to the comparative CT (cycle threshold) method, also referred to as the
2 ─ ∆∆CT method. The formula used: [2─ [Mean

Cts target – Mean Cts reference)

] for each

sample. For each treatment group the mean ± SE value has been plotted.

Measurement of cytokines in the plasma and the colonic tissue
At day 10, we measured cytokines in the plasma and the colonic tissue
homogenate using a bead based immunoassay (Lincoplex) multianalyte
detection platform (Luminex - Mouse Cytokine Panel). Values are expressed in
picograms per milliliter and as mean ± SE, n=6 - 8/ group.
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Western Blot Analyses
Proteins were extracted from each colon (n=6) per treatment group. Equal
amounts of protein lysate were separated on 10% SDS-PAGE and transferred to
nitrocellulose membrane (Bio-Rad, Hercules, CA). We blocked with 5% non-fat
milk and the blots were washed in TBS-T and incubated with the primary
antibody at 40C, overnight (mouse anti-β-actin, mouse anti-COX2). Next day,
blots were washed with TBS-T and incubated for 2h with horseradish peroxidaseconjugated secondary antibody (goat anti-mouse β-actin or COX2 - Santa-Cruz
Biotechnology). After careful washing the membrane was visualized by enhanced
chemiluminescence (ECL)

Bone marrow-derived dendritic cells generation
A single-cell suspension of bone marrow from femur and tibia bones of C57Bl/6
mice was obtained by flushing the bones with cell culture media, RPMI 1640
medium (HyClone, Thermoscientific) supplemented with 10% fetal bovine serum
(Atlanta Biologicals), L-glutamine, HEPES and Penicillin/Streptomycin
(Invitrogen). After spinning, the cell pellet was resuspended in dendritic cell
media (cell culture media supplemented with 20% F10.9 cell supernatant
containing GMCSF) and plated at a concentration of 4x106 cells. On day 9, both
adherent and non-adherent fraction of cells were harvested and washed free of
dendritic cell media. Cells were counted before treating with the appropriate
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ligands. On day 9, the cultures contained 85% CD11c+ bone marrow-derived
(BM) dendritic cells (DCs).

Ligand activation of nuclear receptors
On day 9, BM - DCs were plated at 1X106 cells/ ml in TC-treated 6-well plates
(Falcon), in 3 replicates per treatment. Cells were incubated for 24 hours with
10µM Rosiglitazone (R) (Cayman Chemical), 1µM of 9-cis-retinoic acid (RA)
(Sigma) and their combination. Cells were treated with DMSO or were incubated
with 1 µg/ml LPS at the time of ligand treatment. At 24 hours, cells were
harvested and washed extensively to remove residual ligands. RNA was
extracted using Trizol (Invitrogen) reagent method. cDNA was obtained using
Transcription High Fidelity cDNA Synthesis Kit (Roche). Specific mRNA levels
were quantified by real time reverse transcription-polymerase chain reaction (RTPCR), using the IQ iCycler [Bio-Rad), and SYBR Green qPCR Supermix (BioRad). Primers were designed using the Primer 3 software (SourceForge) and the
sequences are shown in Table 3.1.

Statistical analysis
Data are expressed as Mean ± SE. Data were analyzed using one-way analysis
of variance (ANOVA) (GraphPad Prism 5) followed by Tukey’s test with
significance accepted at p < 0.05. Body weight data were analyzed by one-way
ANOVA with repeated measures on time. Significance was accepted at p < 0.05.
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Results
The severity of DSS- induced colitis is decreased in mice receiving Adiponectin
adenovirus
Viral vector administration did not alter the weight or other clinical parameters
prior to DSS protocol. At the end of the DSS administration, mice receiving the
reporter gene and DSS - the V+DSS group - had a significant drop in weight
(Figure 3.1A, p=0.001), and hematocrit (Figure 3.1B, p=0.02) consistent with
increased severity. The postmortem exam of colons from V+DSS mice group
revealed swollen and shortened colons compared to control (Ctr – water+LacZ)
and mice receiving Adiponectin adenovirus and DSS (AN+DSS) (Figure 3.1C,
p=0.01). Microscopically, colitis was mild in the AN+DSS group as compared with
significant mucosal ulceration, crypt abscesses and altered architecture present
in V+DSS mice. Proliferating cell nuclear antigen (PCNA) staining revealed a
significant increase in crypt proliferative activity in AN+DSS group as compared
to the V+DSS group (Figure 3.1) consistent with a normal epithelial turnover.
Mice in the AN+DSS group had an increased mRNA expression, colonic and
plasma level of adiponectin at the end of the study compared with V+DSS and
Ctr group (Figure 3.2).

Mice that overexpressed adiponectin (AN+DSS) showed decreased proinflammatory cytokines expression during DSS - induced colitis
During colitis, inflamed colonic tissue can become a source of inflammatory
cytokines like tumor necrosis factor (TNFα) interleukin 1 (IL1β), and the key
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factor in the recruitment of macrophages, the monocyte chemoattractant protein
(MCP-1). In our study, adiponectin overexpression had a protective effect and
led to the downregulation of aforementioned pro-inflammatory cytokines, as well
as of chemokine (C-C motif), receptor2 (CCR2), the receptor for the MCP1 , as
compared with control (Ctr) or V+DSS mice groups (Figure 3.3). Consequently, a
lower expression of MCP1 and CCR2 cytokines could decrease the ability to
recruit macrophages into the colonic tissue115.

Anti-inflammatory cytokines were increased in mice overexpressing adiponectin
IL10 is known to limit the extent of intestinal inflammation during colitis by
inhibiting the macrophage and Th1 cells production of pro-inflammatory
cytokines116. Administration of adiponectin adenovirus to AN+DSS mice group
upregulated the expression of the anti-inflammatory cytokine IL10 and its plasma
level (Figure 3.4A, B) after DSS-induced colonic injury. DSS model of colitis
leads to significant epithelial damage and recruitment of inflammatory cells 117-118.
Secretory leukocyte protease inhibitor (SLPi) released by epithelial cells and
macrophage can limit tissue destruction by neutralizing proteases and
downregulating pro-inflammatory cytokines 119-120. We observed a robust
induction of SLPi in mice receiving the adiponectin adenovirus (Figure 3.4D,
p=0.001). Independent of its anti-protease activity, the SLPi can limit
macrophage nitric oxide (NO) and TNFα production120. We hypothesized that
higher IL10 and SLPi expression in adiponectin treated mice will promote M2
(alternatively activated) macrophages, associated with the repair processes. The
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mRNA expression of arginase 1 (Arg 1), a marker of this macrophage phenotype,
was increased 3 fold in AN+DSS group as compared to Ctr and V+DSS mice
(Figure 3.4C, p=0.002).

Adiponectin administration reduces the pro-inflammatory adipokines during DSS
induced colitis
Adipose tissue derived hormones like angiotensin II and osteopontin can fulfill
pro-inflammatory cytokine-like functions 121-122. Both adipokines have been
shown to promote inflammation in the DSS model of colitis 81,123. Furthermore,
they are capable of downregulating adiponectin and/or its receptors124. We
hypothesized that adiponectin treatment will prevent activation of the reninangiotensin system (RAS) and osteopontin and complete a regulatory loop that
protects mice from colitis. Our study showed a 3-fold increase in both
angiotensinogen (angiotensin precursor) and osteopontin expression in mice
receiving DSS (Figure 3.5A, 3.5D). Angiotensin II is generated through the
activity of angiotensin converting enzyme (ACE) while its inflammatory signal
requires the angiotensin receptor 1 (AT1)125. There was no significant change in
ACE and AT1 expression during DSS colitis in the V+DSS group receiving the
reporter gene and DSS (Figure 3.5B, 3.5C) compared to the control group. In
contrast, higher adiponectin levels in AN+DSS group effectively downregulated
(3 fold) both ACE and AT1 (Figure 3.5B, 3.5C) and correlated with a protective
effect from DSS-induced colitis.
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Adiponectin upregulation in mice with colitis decreased the endoplasmic
reticulum (ER) stress response and the mediators of apoptosis
Recent evidence suggests that endoplasmic reticulum (ER) stress is important in
the initiation and regulation of gut inflammation126. Human and experimental
models of inflammatory bowel diseases are associated with cellular stress due
to accumulation of misfolded proteins within the colonic epithelium127.
Endoplasmic reticulum - binding protein (BIP/ Grp78) acts as an intracellular
sensor and is considered a marker of ER stress. Adiponectin treatment
decreased BIP mRNA expression in AN+DSS mice (Figure 3.6A) implying a
lower level of ER stress. In addition, since ER stress response is coupled to the
cell death program, we investigated the mRNA expression of two pro-apoptotic
molecules: C/EBP Homologous Protein (CHOP) and Caspase 12 (Casp12).
There was a 2.5 fold downregulation of the expression of both pro-apoptotic
genes in the AN+DSS mice compared with V+DSS that expressed the reporter
gene (Figure 3.6B, C). Cooperation between cyclooxygenase 2 (COX-2) and
TLR4 signaling pathway insures optimal proliferation and protection against
apoptosis in the injured intestine128. In our experiment, adiponectin
overexpression correlated with decreased disease severity and a three-fold
increase in colonic COX2 expression (Figure 3.6D, E).

Treatment with the mammalian adiponectin homolog- osmotin- offered similar
protection against DSS-induced colitis
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Osmotin, and many of its homologs, functions as defense proteins of the plant
innate immune system 129. Osmotin is an adiponectin homolog and can signal
through adiponectin receptors 1 and 2. Specifically, we showed that osmotin
could activate the adiponectin target, AMP kinase in mammalian myocytes via
adiponectin receptors130. In our current experiment, osmotin was delivered via
mini-osmotic pumps for 2 weeks and colitis was induced by administering 3.5%
DSS in the drinking water for 7 days. The osmotin treatment group OSM+DSS
maintained their body weight during DSS injury while the group receiving saline
(DSS group) had considerable weight loss (Figure 3.7 A). Importantly, none of
the mice receiving osmotin developed hematochezia, a marker of severe colitis,
as evidenced by Osm+DSS group hematocrit values in the range of control mice
(Figure 3.7B). Similar to the adiponectin overexpression experiments, osmotin
treatment induced a 5 fold increase in plasma level of the anti-inflammatory
cytokine IL10 (Figure 3.7D). There were no statistically significant differences in
colonic and plasma levels of adiponectin between the experimental groups (data
not shown).

PPARγ agonists and retinoic acid reversed the state of adiponectin resistance in
dendritic cells.
Bone marrow (BM) derived dendritic cells (DCs) fulfill a major role in the initiation,
maintenance and propagation of immune responses. In the gut, bacterial stimuli
such as E. coli lipopolysaccharide (LPS) activate the dendritic cells through tolllike receptor (TLR) 4 to induce the expression of IL-12 and initiate a Th1
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response131. PPARγ agonists have been shown to inhibit TLR induced activation
of DCs132. Furthermore, intestinal epithelial cells release retinoic acid and drive
the development of tolerogenic subtype of DCs that express the antiinflammatory cytokine IL10133. Moreover, the anti-inflammatory adipokine –
adiponectin - has been shown to induce IL10 release from DCs134. We
hypothesized that bacterial derived LPS induces a state of adiponectin resistance
in DCs by downregulating its main receptors – adiponectin receptor 1 & 2. Bonemarrow derived DCs from C57Bl/6 mice were cultured in the presence or
absence of LPS (Figure 3.8). There was a 3-fold decrease in both adiponectin
receptors mRNA expression following LPS exposure (Figure 3.8A, B, C).
Administration of Rosiglitazone (R) – a PPARγ agonist – and retinoic acid (RA –
9-cis-retinoic acid) restored the expression of both adiponectin receptors in the
presence of LPS treatment (Figure 3.8A, B, C). Importantly, the combination of
PPARγ agonist and retinoic acid [R/RA = Rosiglitazone + 9-cis-retinoic acid) had
a synergistic effect and more than doubled the secretion of the anti-inflammatory
cytokine IL10 in DCs (Figure 3.8D).

Discussion

Adiponectin is unique among adipokines because its circulating levels are
inversely related to the adipose mass135. Adiponectin gene contains a signal
sequence, a collagen like domain, and a globular domain similar to the
complement factor C1q. Our study indicates that adiponectin treatment can
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significantly ameliorate colonic inflammation in the murine DSS model.
Overexpression of adiponectin restored normal mucosal architecture and
reduced the production of potent inflammatory cytokines and adipokines. The
first evidence for a protective role came from the Nishihara group42. They
demonstrated that adiponectin treatment protects adiponectin KO mice from DSS
induced colitis. Meanwhile, no benefit was noted in TNBS model of colitis,
suggesting the fact that this model might be more dependent on T cells, while the
adiponectin has a greater influence on the innate immunity. This is also
supported by the fact that T cells from either wild type or adiponectin KO produce
similar amounts of pro-inflammatory cytokines IL-6, IL-17, TNFα, and IFNγ upon
activation with CD3/CD28 antibody136.
In our experiment the mice overexpressing adiponectin showed a
reduction in the colonic TNFα, IL1β, as well as colonic and plasma IL-6 (data not
shown). On the other hand, adiponectin treatment significantly elevated the IL10
level within the colon and plasma. This observation is in agreement with in-vitro
studies whereby adiponectin induced macrophage IL10 expression137. In contrast
to our findings and Nishihara's group, a recent study showed that adiponectin KO
mice are protected from DSS and TNBS colitis, and adiponectin treatment
induces inflammation41. The authors have further shown that colonic explants
from treated mice released more IL-6. Differences in adiponectin KO mice have
been invoked since only this group showed high basal TNF-α production and
increased susceptibility to LPS. Several recent studies confirmed that
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adiponectin effectively blocks LPS induced release of pro-inflammatory cytokines
and thus, support an anti-inflammatory role 50,138.
Moreover, a study that compared the outcome of colitis in IL10 KO and
adiponectin/IL10 double KO found no differences136. It was concluded that
adiponectin does not play a role in that colitis model. In accordance with our
experiments, and published data 50,139 we believe that IL10 production is
paramount for the anti-inflammatory role of adiponectin in colitis. Therefore, the
results seen in IL10 KO mice are expected. Furthermore, if adiponectin had
promoted inflammation, the double KO (adiponectin/IL10) mice would have had
decreased morbidity and mortality compared to IL10 single KO.
Adiponectin induced IL10 may promote alternative activation of
macrophages (M2) and resolution of chronic inflammation. We now show that
adiponectin treatment also resulted in higher colonic expression of arginase-1 a
marker of such macrophages140. Adipose tissue macrophages from lean mice
express many genes characteristic of M2 (alternatively activated phenotype)
macrophages 141, including heparin–binding lectin (Ym1), arginase-1, and IL10.
Diet-induced obesity (low adiponectin state) decreases expression of these
genes while increasing expression of those encoding TNF-α and nitric oxide
synthase (NOS) 2 that are characteristic of classically activated (M1)
macrophages 141. Furthermore, AMP-activated protein kinase (AMPK), the kinase
that translates adiponectin signaling, suppresses proinflammatory responses and
promotes macrophage polarization to an anti-inflammatory - M2 functional
phenotype72. Consistent with these observations, macrophages from adiponectin
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KO mice have lower M2 markers142. Influx on leukocytes during colitis requires
coordinated expression of chemokines and their receptors143. In our study, we
found that adiponectin treatment effectively downregulated both MCP-1 and
CCR2. It is known that CCR2-/- mice are protected from DSS colitis and have
increased IL10/TNFα ratio similar to our observations144.
Leukocytes infiltrate the inflamed gut and breach the epithelial barrier by
releasing serine proteases. Epithelial cell, in turn, produce secretory
leukoprotease inhibitor (SLPi) to block their activity as well as exert broad
antimicrobial properties145. Mice receiving adiponectin, in our experiments had a
significant upregulation of SLPi expression. This is also important because
leukocyte proteases can cleave HMW adiponectin – the main anti-inflammatory
moiety - and increase the amount of globular and LMW forms52. In vitro
experiments have shown that globular adiponectin induces NF-kB and proinflammatory cytokines, but prolonged exposure blocks further activation. In
contrast, HMW adiponectin can quickly prevent NF-kB activation53. Thus,
indirectly, SLPi may modulate its activity at sites of inflammation. Mucosal SLPi
expression is decreased in Crohn's Disease patients146, and this observation
adds to the clinical relevance of our study.
In addition to adiponectin, other adipokines can modulate colitis. We now
show that adiponectin treatment downregulates the proinflammatory adipokines
angiotensinogen and osteopontin in experimental colitis. Pharmacological
blockade of the renin – angiotensin (RAS) system as well as absence of
osteopontin protects mice from DSS colitis 81,123. In our study, adiponectin had
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broad effects on the renin-angiotensin system reducing the expression of
angiotensinogen, angiotensin converting enzyme (ACE) and angiotensin receptor
1 (AT1). Blockade of angiotensin can increase adiponectin levels and thus a
regulatory loop may be established. A similar mechanism may operate in the
case of osteopontin since KO mice have lower adiponectin levels both, under
basal conditions and during DSS colitis (unpublished observation).
Adiponectin has a structure similar to complement 1q and TNFα.
Interestingly, the immune system in plants utilizes thaumatin domain proteins
such as osmotin, as defense effectors [35]. To date, Osmotin is the only
thaumatin domain protein that has been reported to act as an adiponectin mimic
in mammalian cells 130,147. Similar to adiponectin treatment we noticed a
beneficial effect of Osmotin in DSS colitis. Mice that received a two-week infusion
of Osmotin showed an improved clinical outcome that correlated with a marked
elevation of plasma IL10 level. Although Osmotin homologs are ubiquitous in
plants and occur in significant amounts in edible plant parts, none has been
examined for adiponectin-like activities. Our results suggest that Osmotin and
related plant proteins are potentially promising and accessible treatments for
IBD.
Decreased adiponectin levels during colitis may be secondary to TLR
triggered inflammatory response. In the small intestine, the DCs precursors
differentiate from circulating inflammatory monocytes and acquire mucosal
functions via micro-environment cues148. During IBD, dysfunctional DCs may act
by initiating abnormal T cell responses to the enteric environment and release of

82

proinflammatory cytokines. Activators of PPARγ are anti-inflammatory and have
been proposed as therapeutic agents for the treatment of Th1-type inflammatory
diseases. For example, rosiglitazone has been shown to enhance the production
of the anti-inflammatory IL10 from activated human mature monocyte-derived
dendritic cell149. This activity is conditioned by the retinoic acid (RA - a metabolite
of vitamin A). Our current experiments in bone marrow derived DCs indicate that
bacterial LPS downregulated adiponectin and its receptors. The conjugated
effects of PPARγ agonists and retinoic acid reversed this state of adiponectin
resistance. Moreover, this recovery was accompanied by a marked induction of
IL10 expression. Our data is in agreement with the observation that PPARγ
agonists induce adiponectin receptor expression in macrophages109. Additionally,
it may further explain the protective effect of PPARγ activation in IBD colitis 35,110.
Endoplasmic reticulum (ER) stress response may contribute to epithelial
damage during DSS-induced colitis as well as in patients with IBD150. IL10
mediated p38 mitogen-activated protein kinase (p38MAPK) signaling can block
activation of the ER stress sensor – endoplasmic reticulum-binding protein (BIP)
- after exposing intestinal cells to TNFα 83. Adiponectin can induce IL10 and
activate p38MAPK 151-152. We now show that adiponectin treatment decreased
ER stress response. Furthermore, it downregulated the expression of caspase12 (CASP12) which plays a central role in ER stress induced apoptosis 153.
Epithelial cyclooxygenase 2 (COX-2) is induced during episodes of inflammation
and mediates toll-like receptor 4 (TLR4) dependent mucosal repair 128,154. COX2-/- mice are more susceptible to DSS-induced colitis due to their inability to
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produce prostaglandin E2 (PGE2)155. The finding of enhanced COX-2 production
in mice overexpressing adiponectin and reduced ER stress markers points
toward a significant protective effect of adiponectin in gut mucosa during
inflammatory situations.
In summary, we provide evidence that adiponectin and its plant homolog –
osmotin - have an anti-inflammatory role in an established model of experimental
colitis. In addition to altering the cytokine milieu, adiponectin may operate in
complex regulatory networks that involve downregulation of pro-inflammatory
adipokines angiotensin and osteopontin. Furthermore, adiponectin modulates the
expression of epithelial protective factors, cellular stress response and immune
cell traffic. In situations where adiponectin secretion is deficient, Osmotin, a plant
derived adiponectin homologue or PPARγ agonists may restore its protective
effects. Importantly, novel therapeutic strategies could be developed in order to
mimic or enhance the anti-inflammatory action of adiponectin.

Figure Legends

Figure 3.1. The severity of DSS-induced colitis is decreased in mice receiving
Adiponectin adenovirus. Mice were randomly assigned to three i.v. treatment
groups: Control (Ctr) and the V+DSS groups received adenovirus reporter gene
while the AN+DSS group received adenovirus adiponectin gene. The Ctr group
was placed on water for 10 days. The V+DSS and AN+DSS groups were
administered 3.5% DSS in drinking water for 7 days followed by 3 days of water.
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(A) Body weight change between the last and first day of the experiment. (B)
Hematocrit and (C) colon length at the end of the experiment. Data are
expressed as mean ± SE, n=6/group. Left panels: Immunohistochemistry for
epithelial cell proliferative index (PCNA) of the colonic tissue of Ctr (upper panel),
V+DSS (middle panel), and AN+DSS (lower panel).
Figure 3.2. Efficacy of adenoviral delivery. Colonic adiponectin was increased at
mRNA (A) and protein level (C) and correlated with plasma level (B) in mice that
received adiponectin adenovirus (AN+DSS).

Figure 3. 3. Expression of pro-inflammatory cytokines during DSS-induced colitis
was decreased in mice overexpressing adiponectin (AN+DSS). Colonic (A)
TNFα, (B) IL1β, (C) MCP1, (D) CCR2 gene expression. Data are expressed as
mean ± SE, n=6/group
Figure 3.4. Adiponectin treatment promoted an anti-inflammatory milieu during
DSS administration. Increased IL10 colonic mRNA (A) and corresponding (B)
plasma level in mice overexpressing adiponectin (AN+DSS). (C) Increased
alternative macrophage (M2) marker - arginase 1- and (D) epithelial secretory
leukoprotease inhibitor, consistent with limited tissue destruction in mice
overexpressing adiponectin (AN+DSS). Data are expressed as mean ± SE,
n=6/group
Figure 3.5. Adiponectin treatment reduces the pro-inflammatory adipokines
during DSS induced colitis. Angiotensinogen, the only known precursor of the
pro-inflammatory angiotensin II was decreased (A) in AN+DSS group. (B)
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Adiponectin overexpression downregulated the angiotensin II receptor 1 and the
enzyme responsible for its generation (C) ACE. Adiponectin treatment reduced
the colonic expression of the pro-inflammatory adipokine - osteopontin (D). Data
are expressed as mean ± SE, n=6/group
Figure 3.6. Adiponectin reduced cellular stress and apoptosis during DSS
induced colitis. (A ) Decreased mRNA gene expression of endoplasmic reticulum
stress response marker – BIP – and related pro-apoptotic factors – CHOP and
Casp12 (B, C) during DSS colitis in mice overexpressing adiponectin (AN+DSS).
Colonic COX-2 exerts proliferative and anti-apoptotic effects. High levels of
adiponectin in AN+ DSS mice correlated with increased colonic COX-2 mRNA
gene expression (D) and protein level (E). Data are expressed as mean ± SE,
n=6/group
Figure 3. 7. Osmotin - a plant derived adiponectin homolog - is beneficial in DSS
colitis model. Saline (for the Ctr and DSS groups) or Osmotin (for the Osm+DSS
group) were delivered as a 2 weeks infusion that overlapped the 10 days of 3.5%
DSS colitis protocol. (A) Change in body weight between last and first day of
DSS protocol. (B) Hematocrit at the end of the experiment. Osmotin treatment
(Osm+DSS group) prevented weight loss and hematochezia during colitis. (C, D)
Increased colonic and plasma level of the anti-inflammatory cytokine IL10 during
DSS colitis in mice receiving Osmotin (Osm+DSS). Data are expressed as mean
± SE, n=8/group
Figure 3.8 PPARγ agonist and retinoic acid reversed the LPS induced
adiponectin resistance in dendritic cells. Murine, bone marrow derived dendritic
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cells were activated with LPS in the presence or absence of PPARγ agonist (R =
rosiglitazone) and retinoic acid (RA -9-cis-retinoic acid). LPS did not affect
dendritic cells’ adiponectin expression while rosiglitazone induced it (A). In the
presence of LPS, both adiponectin receptors were downregulated (B, C).
Rosiglitazone and retinoic acid acted synergistically to restore adiponectin
receptors expression (B, C) and concurrently increased IL10 gene expression
(D). Data are expressed as mean ± SE, n=3 replicates/treatment group.
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Figure 3.1 The severity of DSS-induced colitis is decreased in mice receiving
Adiponectin adenovirus
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Figure 3.2 Efficacy of adenoviral delivery
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Figure 3.3 Expression of pro-inflammatory cytokines during DSS-induced colitis
was decreased in mice overexpressing adiponectin (AN+DSS)
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Figure 3.4 Adiponectin treatment promoted an anti-inflammatory milieu during
DSS administration
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Figure 3.5 Adiponectin treatment reduces the pro-inflammatory adipokines during
DSS induced colitis
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Figure 3.6 Adiponectin reduced cellular stress and apoptosis during DSS induced
colitis
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Figure 3.7 Osmotin - a plant derived adiponectin homolog - is beneficial in DSS
colitis model
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Figure 3.8 PPARγ agonist and retinoic acid reversed the LPS induced
adiponectin resistance in dendritic cells

Copyright @ Springer Publishing House
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Chapter Four
The content of Chapter 4 has been published in the Journal of Inflammatory
Bowel Disease. Permission to reproduce this material has been obtained from
John Wiley & Son publishing company.

ROLE OF THE XENOBIOTIC RECEPTOR IN INFLAMMATORY BOWEL
DISEASE
Synopsis
Background: Gene-environment interplay modulates Inflammatory Bowel
Diseases (IBD). Dioxin-like compounds can activate the Aryl Hydrocarbon
Receptor (AhR) and alter macrophage function as well as T cell polarization. We
hypothesized that attenuation of the AhR signaling pathway will ameliorate colitis
in a murine model of IBD.
Design: DSS colitis was induced in C57BL/6 AhR null mice (AhR –/–),
heterozygous mice (AhR – /+), and their wild type (WT) littermates. Clinical and
morphopathological parameters were used to compare the groups. Patients: AhR
pathway activation was analyzed in biopsy specimens from 25 IBD patients and
15 healthy controls.
Results: AhR –/– mice died before the end of the treatment. However, AhR – /+
mice exhibited decreased disease activity compared to WT mice. The AhR – /+
mice expressed less proinflammatory cytokines such as TNFα (6.1 versus 15.7
fold increase) and IL17 (23.7 versus 67.9 fold increase) and increased anti+/+

inflammatory IL-10 (2.3 fold increase) compared with the AhR
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mice in the

colon. Colonic macrophage infiltration was attenuated in the AhR – /+ group. AhR
and its downstream targets were significantly upregulated in IBD patients versus
control (CYP1A1 – 19.9, and IL8- 10 fold increase).
Conclusion: Attenuation of the AhR receptor expression resulted in a protective
effect during DSS-induced colitis, while the absence of AhR exacerbated the
disease. Abnormal AhR pathway activation in the intestinal mucosa of IBD
patients may promote chronic inflammation. Modulation of AhR signaling
pathway via the diet, cessation of smoking or administration of AhR antagonists
could be viable strategies for the treatment of IBD.

Introduction
Inflammatory Bowel Disease (IBD) is characterized by an inappropriate immune
response to commensal flora. 156-157 In Western countries, 1 in 200 patients are
affected by Ulcerative Colitis (UC) or Crohn’s Disease (CD), the major forms of
IBD and their incidence is steadily increasing. 158 The causes of IBD are
unknown and the diagnosis is based on clinical, endoscopic, radiological and
histological criteria. 159 Differences between familial and geographic clustering
point toward environmental factors. In Caucasians, smoking has the strongest
association with the severity of the gut inflammation. 160-161
Aryl Hydrocarbon receptor (AhR) is the only known receptor for dioxin, a
potent immunomodulating environmental contaminant. Studies showed that
cigarette smoke contains dioxins and dioxin-like chemicals. 162-164 The unbound
AhR is present in the cytoplasm of all immune system cells. Furthermore, many

97

genes involved in immune regulation possess multiple dioxin response elements
(DREs) in their promoter region. 94,165 Studies performed in AhR –/– mice have
shown an enhanced inflammatory response to cigarette smoke or endotoxin, with
elevated levels of tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6). 166-167
AhR is essential in the regulation of cell cycle , lipid metabolism 168 circadian
rhythm 169 and immune response. 170 Although AhR seems to be a crucial cofactor in regulation of both homeostasis and inflammation, its role in the gut
autoimmune pathology is poorly described. Surprisingly, sustained activation of
AhR by its high affinity, prototypical agonist, 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin
(TCDD), resulted in altered bone marrow and thymic development, as well as
susceptibility to infectious diseases and cancer in mice. 171-172 Collectively, these
observations suggest that a low to normal activation of AhR is beneficial for the
protection against environmental insults, and represents an important link
between environment and chronic diseases.
Our preliminary experiments indicated that AhR –/– mice are highly
sensitive to DSS-induced colitis. In the current study, we examined the outcome
of DSS-induced colitis in wild type and AhR heterozygous mice. Interestingly,
moderation of the AhR signaling pathway in the AhR heterozygous mice was
sufficient to ameliorate colitis. We also provide evidence that the level of AhR
expression correlates with the profile of cytokines, adipokines and cellular stress
response. These data indicate that attenuation of the AhR signaling pathway
corresponds to an attenuated inflammatory response in the colon in disease-free
conditions and during experimentally induced colitis. Furthermore, we extended
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our observations in IBD patients were AhR pathway was significantly upregulated
when compared to healthy controls.

Materials and Methods
Subjects and sample collection
Colonic biopsies were obtained from 15 healthy controls and 25 IBD (Crohn’s
Disease) patients. Control subjects were healthy individuals who underwent
screening colonoscopy and had no inflammatory bowel conditions. IBD patients
had an established diagnosis, based on standard endoscopic, radiologic, and
histologic criteria. Informed consent was obtained before participation and the
study protocol was approved by the Institutional Review Board of the University
of Kentucky.
To examine the AhR activation in the lower digestive tract, biopsies were
taken from the colon during standard colonoscopy. Two biopsies from each
subject were fixed in formalin or RNA Later until analysis. The formalin fixed
subset of biopsies was subject to standard histological staining and fluorescent
immunohistochemistry. The RNA later subset of biopsies was used to assess the
total mRNA using MagnaPure Compact RNA Isolation Kit (Roche). cDNA was
obtained using Transcription High Fidelity cDNA Synthesis Kit (Roche). Specific
mRNA levels were quantified by real time reverse transcription-polymerase chain
reaction (RT-PCR), using the IQ iCycler (Bio-Rad), and SYBR Green qPCR
Supermix (Bio-Rad). Primers were obtained from SABiosciences, Frederick, MD.
The mRNA levels for test genes were normalized to reference gene according to
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the comparative CT method also referred to as the 2 ─ ∆∆CT method. The formula
used: (2─ (CT test – CT reference)) x 100%.

Animal treatments and sample collection
Male, 3 months old C57BL/6 and AhR –/– mice (Jackson Laboratory), or AhR – /+
mice bred in-house to C57BL/6 mice (n = 10 mice/group) were housed in a
pathogen-free environment with free access to food and water. Mice were
administered 3.5% (wt/vol) DSS (ICN Biochemical) in water for a week, followed
by 3 days of water only. Body weight, stool consistency and rectal bleeding were
monitored daily. On day ten, mice were euthanized with ketamine/xylazine
(100/10 mg/kg ip) for blood and tissue harvest. The colons were removed and
perfused with phosphate-buffered saline (PBS - pH 7.4), and measured. Half of
each colon was fixed in RNAlater (Qiagen), and stored at -20°C. The other half
was made in a “swiss roll”, cut and fixed in 10% buffered formalin (Sigma
Chemical). The Animal Care and Use Committee at the University of Kentucky
approved all procedures.

Analysis of mRNA gene expression levels in mouse colonic tissue
On day 10, total RNA was purified using MagnaPure Compact RNA Isolation Kit
(Roche) from whole colon tissue and cDNA was obtained using Transcription
High Fidelity cDNA Synthesis Kit (Roche). Specific mRNA levels were quantified
by real time reverse transcription-polymerase chain reaction (RT-PCR), using the
IQ iCycler (Bio-Rad), and SYBR Green qPCR Supermix (Bio-Rad). Primers were

100

designed using the Primer 3 software (SourceForge) and the sequences are
shown in Table 1 (supplemental material).
The mRNA levels for test genes were normalized to reference gene according to
the comparative CT method also referred to as the 2 ─ ∆∆CT method. The formula
used: (2─ (CT test – CT reference)) x 100%.

Measurement of cytokines in the colonic tissue
At day 10, we measured cytokines in the colonic tissue homogenate using a
bead based immunoassay (Lincoplex) multianalyte detection platform (Luminex Mouse Cytokine Panel). Values are expressed in picograms per milliliter and as
mean ± SE, n=10 / group.

Histology
Serial sections (5 -7 μm) of paraffin embedded colons (swiss roles) were stained
with hematoxylin and eosin. A pathologist blinded to the group allocation
assessed the severity of colitis. The scoring system evaluated the following
characteristics: (1) percentage of area involved, (2) number of follicle aggregates,
(3) edema, (4) erosion/ulceration, (5) crypt loss, and (6) infiltration of
mononuclear and polymorphonuclear cells. The total score ranges from 0 to 26.
173

Proliferating Cell Nuclear Antigen (PCNA) assay
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The sections were deparaffinized and treated with Antigen Retrieval Solution
(DAKO, Carpinteria, CA) followed by incubation in 0.3% H2O2-methanol for 10
min, and wash. Sections were incubated in normal blocking serum for 90 min
followed by overnight incubation in primary antibody, NCL-PCNA (1:200)
(Novocastra, Leica Microsystems) at 4°C. The biotinilated secondary antibody
(Elite ABC kit, Vector) was then applied for 2 hours. The slides were
counterstained with Methyl Green (DAKO). Images were taken with an Olympus
BX51 microscope (Olympus America Inc.).

Fluorescent Immunohistochemistry
Formalin-fixed, paraffin embedded colon sections (5-7 μm) placed on coated
slides were sequentially deparaffinized and rehydrated using xylene and ethanol.
Slides were then treated for 10 min with a citric acid-based antigen-unmasking
solution (Vector Laboratories, Burlingame, CA). Next, slides were incubated for 1
hour at room temperature in normal blocking serum (1% in PBS) and incubated
overnight at 4°C with the respective primary antibody (dilution 1:50): Angiotensin
II (BGN/0856/21) - a mouse anti-human monoclonal antibody, AT1 (306: sc-579)
- a rabbit anti-human polyclonal antibody or ACE (H-170: sc-20791) - a rabbit
anti-human polyclonal antibody, (Santa Cruz Biotechnology, INC, CA). On the
second day, after washing, sections were incubated for 1 h with a mixture of Cy2conjugated goat anti-mouse IgG and Cy3-conjugated goat anti-rabbit IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA, catalog numbers 115225-146 and 111-165-144). Sections were counterstained with 4’, 6-diamidino-2-
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phenylindole dihydrochloride (DAPI) (Molecular Probes Invitrogen, Eugene, OR)
to visualize nuclei, and mounted with VECTASHIELD® medium (Vector
Laboratories, Burlingame, CA). Images were taken with an Olympus BX51
microscope, using a 20x objective. We generated the composite images using
Image-ProPlus 5.0 (Media Cybernetics, Inc.) software.

Statistical analysis
Data are expressed as Mean ± SE. Data were analyzed using unpaired t-test and
one-way analysis of variance (ANOVA) (GraphPad Prism 5) followed by Tukey’s
test with significance accepted at p < 0.05. Body weight data were analyzed by
one-way ANOVA with repeated measures on time. Survival percentage has been
calculated using Kaplan-Meier method. Significance was accepted at p < 0.05.

Results
The severity of DSS- induced colitis is decreased in AhR -/+ mice
Preliminary experiments showed that AhR KO mice do not survive beyond day 7
to DSS induced colitis (Figure 4.1A). Therefore, in the current study, AhR – /+ and
WT mice were analyzed. There was circa 50% reduction in AhR mRNA
expression in colonic tissue of
AhR – /+ mice that was maintained during colitis (Figure 4.1B). Before DSS
administration, there were no differences in body weight among groups. On day
ten, WT mice lost significantly more weight (Figure 4.1C. p=0.001), had a
significant drop in the hematocrit (Figure 4.1D, p=0.002), and the postmortem
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exam revealed swollen and shortened colons compared to AhR – /+ mice exposed
to DSS (Figure 4.1E, p=0.01). Microscopically, colitis was mild in the AhR – /+
group as compared with significant mucosal ulceration, crypt abscesses and
altered architecture present in WT mice and reflected in the histology score
(Figure 4.1F, p=0.001), and H&E stained colon sections (Figure 4.2A).
Furthermore, Proliferating cell nuclear antigen (PCNA) staining revealed a
significant decrease in crypt proliferative activity in WT group as compared to the
AhR – /+ group (Figure 4.2B), consistent with defective epithelial turnover.
Importantly, there were no significant differences between AhR – /+ with and
without colitis and the control water fed WT mice.

AhR -/+ genotype favors Th2 over Th1 type cytokine expression
The cytokine milieu within the gut defines the outcome of both innate and
acquired immune cells activation. We investigated the expression of classical
Th1/Th2 cytokines previously documented in mice with DSS induced colitis and
IBD patients (27). Wild type mice exposed to DSS developed colitis that was
characterized by increased expression of TNFα gene and protein level (Figure
4.3A, 3B, p=0.001). Importantly, AhR – /+ mice had significantly lower baseline
TNFα gene (Figure 4.3A ) and protein level ( Figure 4.3B) expression as
compared to that in wild type mice and did not change during colitis. Intestinal
macrophages play a central role in the immune response to commensal flora and
become a source of Th1 cytokines in IBD. (28) The mRNA gene expression of
the macrophage marker F4/80 (Figure 4.3C, p=0.018) was downregulated in AhR
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– /+

mice treated with water or DSS. The immunostaining of gut sections from AhR

– /+

mice with colitis showed a significant decrease in macrophage infiltration

(Macrophage-restricted protein-F4/80 - green, Figure 4.7), consistent with a
dampened innate immune response as compared with WT mice with colitis.
Although the monocyte chemoattractant protein (MCP1) expression increased
during colitis in AhR – /+ mice, this was significantly lower compared to wild type
mice (Figure 4.3D, p=0.005). Baseline expression of IL10 within the colon was
similar in control AhR – /+ and WT mice. Nevertheless, during DSS colitis there was
significant upregulation of this anti - inflammatory cytokine only in AhR – /+ mice
(Figure 4.3E, 4.3F, p=0.005). In addition, we observed a more prominent
induction of anti-inflammatory Secretory leukocyte protease inhibitor (SLPi) in
AhR – /+ mice (suppl. Fig 10, p=0.0001) as compared to that in the WT mice
during DSS induced colitis. SLPI is mainly expressed in the colon by the
epithelial cells and is a potent inhibitor of Th1 like cytokines. 174
Th17 to Treg shift occurs during DSS-induced colitis in AhR -/+ mice
Aside from the classical Th1/Th2 paradigm, we further investigated the
expression of master regulators for Th17 and Treg cells during colitis. Under
basal conditions there were no differences between the AhR – /+ mice and WT
(Figure 4.4A-D). During DSS colitis there was a significant up regulation of Treg
specific transcription factor FOXp3 gene expression in AhR – /+ mice as
compared to that in the WT mice (Figure 4.4A, p=0.004). In contrast, the mRNA
expression of Th17 specific transcription factor, RORγ was significantly
downregulated in AhR – /+ mice relative to the WT mice (Figure 4.4B, p=0.021).
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Consistent with the latter finding we observed a significant attenuation of IL17
gene expression and protein level in AhR – /+ mice (Figure 4.4C-D).

Pro-inflammatory adipokines are decreased in AhR -/+ mice during DSS colitis
Mesenteric adipose tissue can become a source of inflammatory adipokines like
angiotensin and osteopontin. Thus, during postmortem collection of the colons,
we carefully removed the adjacent fat tissue. Nevertheless, these mediators can
also be expressed in gut epithelia and lamina propria immune cells. (29-31) We
confirmed that both AhR – /+ and WT C57BL/6 mice express components of the
angiotensin system (Figure 4.5 A-E) as well as osteopontin ( Figure 4.5 D) within
the colon. Pharmacological blockade of renin-angiotensin system has been
shown to decrease the severity of colitis in several mouse models. (30, 32) We
show that AhR – /+ mice treated with DSS presented a significant downregulation
of the only known precursor of angiotensin I/II - angiotensinogen (Figure 4.5A,
p=0.0001), as well as the angiotensin converting enzyme ACE (Figure 4. 5B,
p=0.0048), and angiotensin receptor AT1 (Figure 4.5C, p=0.003) gene
expression compared to the WT group. Importantly, the AhR – /+ mice presented
significant less AT1 mRNA gene expression under basal conditions (Figure 4.5C,
p=0.023). Compared to WT mice with colitis, the immunohistochemistry of colon
sections of AhR – /+ mice with colitis revealed decreased angiotensin II, AT1
receptor (Figure 4.5E) and ACE expression (suppl. Figure 4.11).

Adiponectin, the anti-inflammatory adipokine is increased in AhR -/+ mice during
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DSS induced colitis
Adiponectin, the only known anti-inflammatory adipokine, is considered an
exclusive product of adipose tissue. Here, we show that adiponectin gene is also
expressed in the colon (Figure 4.6A). Next, we asked whether induction of colitis
impairs adiponectin expression, and/or promotes a state of adiponectin
resistance by down regulating its receptors. All the AhR – /+ mice presented a
higher basal adiponectin mRNA gene expression that did not change during
treatment. Importantly, adiponectin mRNA gene expression dropped significantly
in the wild type mice during colitis (Figure 4.6A, p=0.0006). Consequently,
adiponectin receptors (AdipoQ R1 and R2) were downregulated during DSS
colitis in all groups (Figure 4.6 C, D). Interestingly, T-Cadherin mRNA gene
expression, a novel adiponectin receptor that serves to anchor adiponectin to cell
surface 175, was upregulated only in the AhR – /+ mice and not in the WT mice
with colitis (Figure 4.5B, p=0.037). Moreover, AhR – /+ mice exposed to DSS had
a lower expression of Protein of 44 kDa (Erp44) that inhibits the secretion of
adiponectin oligomers from the endoplasmic reticulum (ER). In addition, the ER
oxidoreductase 1-Lα (Ero1-Lα), an ER chaperone that releases adiponectin
trapped by Erp44 had similar expression in all groups. (Figure 4.6D-E, p=0.002).
Therefore, by modulating the ratio of these ER chaperones the attenuated AhR
signaling pathway favors the secretion of the anti-inflammatory adiponectin
during experimentally induced colitis.
.
The AhR+/- mice with DSS induced colitis have less endoplasmic reticulum (ER)
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stress response.
The development of colitis during DSS administration is associated with high
cellular stress due to accumulation of misfolded proteins within the colonic
epithelium. ER binding protein (BIP/ Grp78) acts as an intracellular sensor and is
considered a marker of ER stress 176. X-Box Binding Protein 1 (XBP1) is a
transcription factor induced by ER stress that exerts a protective role and thus
allows cells to recover. 177 In our study we observed a significant downregulation
of ER stress markers BIP (p=0.018) and XBP1 (p=0.002) in the AhR – /+ mice
exposed to DSS as compared to the WT mice with colitis (Suppl. Figure 9). Since
ER stress response is coupled to the cell death program, we investigated the
mRNA expression of two pro-apoptotic molecules: C/EBP Homologous Protein
(CHOP) and Caspase 12 (Casp12). There was a significant downregulation of
the expression of both pro-apoptotic genes only in the AhR – /+ mice exposed to
DSS (Suppl. Figure 4. 9).

AhR pathway is activated in patients with Inflammatory Bowe Diseases.
In this study we have shown that AhR pathway can modulate the inflammatory
response during experimental colitis. Then, using immunohistochemistry we
investigated the pattern of AhR expression in healthy controls and patients with
Crohn’s Disease. In human subjects without IBD, AhR expression was confined
to the epithelial layer (Figure 4. 8C), whereas in Crohn’s Disease there was a
significant influx of AhR+ cells in the lamina propria compartment (Figure 4.8D)
corresponding to pro-inflammatory hematopoietic cells. AhR pathway activation
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was assessed by measuring the expression of its downstream target, CYP1A1.
There was negligible expression in healthy controls while a 19.9 fold upregulation
was noted in IBD patients (Figure 4.8A). IL-8 is a chemokine, which promotes
neutrophil recruitment in patients with IBD. Human IL-8 promoter contains
xenobiotic responsive elements (XRE) and thus can be upregulated by AhR
signaling. 178 Similar to the prototypical AhR target CYP1A1, IL-8 expression was
upregulated 10 fold in patients with Crohn’s Disease (Figure 4. 8B).

Discussion

Although the precise pathogenesis of IBD still needs to be unraveled,
recent studies have reinforced the strong association between smoking, disease
severity, complications and resistance to treatment. 161,179 Mahid et al. found a
greater prevalence of IBD patients in Kentucky, a state that ranks second in the
nation in tobacco production and first in its use. 180 Mainstream cigarette smoke
contains high level of dioxins and dioxin-like chemicals that are known to be
strong inducers of AhR. 162-163 In addition to their prolonged half-life, these
ubiquitous contaminants are highly lipophilic and accumulate in the adipose
tissue181, possibly leading to a prolonged activation of the AhR signaling
pathway. 182
Persistent activation of the AhR has been extensively researched using
TCDD, a high affinity AhR agonist. 183 Administration of TCDD to laboratory
animals induces inflammation by promoting tissue migration of immune cells 184-
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185

, and an increase in pro-inflammatory cytokine expression. 186-187 Surprisingly,

macrophages isolated from mice lacking the AhR produce higher amounts of the
inflammatory cytokines IL-1, IL-6 and TNFα in response to LPS. 188-189 Earlier
studies indicated that AhR null mice develop colitis and rectal prolapse and have
a propensity to develop colon cancer. 190 The inferred conclusion from the data
obtained from either the ligand-activated AhR cell lineages or AhR null mice
clearly states the physiological importance of this receptor in cell growth 191-192,
cell apoptosis 193, elaborate cross-talk with NF-kB 194-195, and ER stress
response. 196
To explore the association between the AhR pathway and IBD
pathogenesis, we induced colitis in AhR - /-, AhR – /+, and AhR + /+ mice. We
found that mice lacking the AhR succumbed early to inflammation while the WT
developed severe colitis. In comparison, the AhR heterozygous mice had a good
clinical outcome during DSS administration and presented little structural
changes in intestinal mucosa architecture.
Macrophages play an important role in the innate immune response to
bacteria. In patients with Crohn’s disease, there is an influx of CD14+
macrophages within the gut, which become a rich source of TNFα. 197 Blockade
of this proinflammatory cytokine induces disease remission in patients with IBD
and in experimental models of colitis. 198-199 We found that AhR – /+ mice express
significantly lower levels of TNFα as compared to that observed in the WT groups
under both, disease-free conditions and during experimentally induced colitis.
Moreover, the expression of the Macrophage-restricted protein F4/80 was
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decreased in the colon of AhR – /+ mice during colitis. It is increasingly
acknowledged that the AhR pathway modulates a number of immune
responses.200 While the specific AhR-induced mechanisms that underlie its
effects on the immune system are poorly understood, numerous genes activated
during the immune response have been found to contain DNA recognition sites
for the AhR/ARNT heterodimers. (47, 48) Furthermore, the AhR pathway has
been shown to play a significant role in the development of both Th17, and Treg
cells. 95 The pathogenic role of Th17 cells as well as defective function of Tregulatory cells has been found in patients with Crohn’s disease and animal
models of IBD. 201-202 In the current study, we show that there is significant
downregulation of the Th17 lineage master regulator, RORγ, with a
corresponding upregulation of Treg transcription factor Foxp3 in the colon of AhR
– /+

mice during colitis. Consistent with these changes, we have also noted a

significant decrease in the IL-17 expression and a corresponding increase in IL10 expression. Thus, the attenuation of the AhR signaling pathway correlates
with the outcome of experimental colitis and the Th17 / Treg balance in the colon.
The adipokines and cytokines secreted by adipose tissue have been
increasingly recognized as bona-fide immune regulators. Angiotensin, a
proinflammatory adipokine is generated from angiotensinogen through the
proteolytic activity of ACE and tissue chymases. AT1a is the main receptor that
mediates the pro-inflammatory actions of angiotensin. 203 Intestinal mucosa is a
rich source of ACE, while macrophages express the full renin-angiotensin
system. Increased ACE was reported in Crohn’s disease patients, while Ace/AT1
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blockade protects mice from experimental colitis. 77,204 In our study, AhR wild
type mice that developed colitis had high expression of the angiotensin system
components. Furthermore, there was a significant increase in lamina propria cells
expressing both angiotensin and AT1a. We have previously shown that AhR
agonists induce expression of angiotensinogen and proinflammatory cytokines in
cultured adipocytes. 181 Our current finding that AhR – /+ mice fail to upregulate
angiotensin system during DSS colitis further implicate this system in AhRmediated inflammation.
Adiponectin, the primary adipokine with anti-inflammatory activity was
downregulated in the wild type AhR mice that developed severe colitis, while the
opposite was found in AhR – /+ group. We have previously demonstrated that AhR
activation downregulates the expression of this adipokine in fat cells. 181 In the
current study, we report that attenuated AhR expression/activity in the AhR – /+
mice, correlates with increased colonic adiponectin and its T-Cadherin receptor
expression during DSS treatment. Moreover, our study indicates that AhR
modulates the expression of ER chaperone proteins that regulate adiponectin
secretion. These correlations might be very important since adiponectin has a
protective role in experimental colitis as recently shown by the Nishihara group.
42

Furthermore, it was demonstrated that adiponectin treatment protects

adiponectin KO mice from developing DSS-induced colitis. In addition,
adiponectin has been shown to induce IL-10205, and thus, promote alternative
activation of macrophages and resolution of chronic inflammation. In our study,
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the increased adiponectin in AhR – /+ mice may have had an important role in
maintaining tissue homeostasis during DSS induced colitis.
Recent studies have shown that an increased endoplasmic reticulum
stress response in epithelial cells promotes colitis. Importantly, mutations in
XBP1, a key component of this response, have been associated with Crohn’s
disease. 126 In the current study, DSS-induced colitis resulted in an increase
expression of ER stress markers in wild-type mice, while they were
downregulated in the AhR – /+ mice. Furthermore, increased IL-10 expression in
the latter group may have also reduced the stress response associated with
colitis. 206 It is also possible that the ER stress response during colitis facilitates
AhR signaling and their reciprocal induction leads to the inflammatory response
associated with DSS induced colitis. 207
The effect of AhR activation on T cells is ligand dependent. TCDD induces
persistent activation of AhR in Treg cells. 94 On the other hand dietary derived,
short acting ligands, such as FICZ (6-formylindolo, 3, 2-b-carbazole) induce Th17
differentiation. 208 The relative abundance of the different ligands, along with the
AhR system polymorphisms may further modulate the response. 93,209 In our DSS
model, AhR activation most likely occurred through dietary (i.e. FICZ) and
endogenous ligands with similar kinetics, thus explaining the upregulation of IL17 and RORγ. The increased expression of colonic macrophages in wild type
mice compared to AhR – /+ further supports the role of this receptor in colitis.
Recent in-vitro studies in macrophages described an ARNT independent, nongenomic pathway downstream of AhR that induces an inflammatory response. 210
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We hypothesize that low AhR expression may be coupled to the classical signal
that downregulates macrophage function whereas increased receptor expression
preferentially activate the non-genomic pathway and hence promotes
inflammation.
Our studies in patients without IBD indicate that AhR is mainly expressed
in the epithelial layer. Nevertheless, this translated in minimal activation of this
pathway and likely fulfills a physiologic role such as cell cycle regulation and
metabolism of diet derived xenobiotics. AhR is important for the development of
Th17 cells and can upregulate human macrophage expression of IL-8.178 These
activities are highly relevant for the ongoing intestinal inflammation of IBD
patients. The robust AhR activation shown in our Crohn’s Disease patients was
secondary to the influx of lamina propria AhR+ mononuclear cells, like macrophages
and T cells. Consistent with this observation, we found high IL-8 expression that
mirrored the AhR classical target, CYP1A1.
In summary, we provide novel evidence that dysregulated expression of
the AhR alters the outcome of colitis. The extreme phenotypes of AhR null and
wild types groups indicate that AhR pathway fulfills both tissue homeostatic and
inflammatory roles. Furthermore, we show that AhR pathway activation
distinguishes Crohn’s Disease patients from healthy controls. Modulation of this
pathway through diet, cigarette smoking cessation, as well as pharmacological
antagonism of the AhR could be viable strategies for the treatment of IBD.
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Figure Legends
Figure 4.1. The severity of DSS-induced colitis is attenuated in AhR – /+ mice.
Mice were administered 3.5% DSS dissolved in water for 7 days followed by 3
days of water. Control mice received water alone for 10 days. (A) Kaplan-Meier
plot showing premature lethality of male AhR– /– when compared with WT and
AhR – /+ littermates (B) AhR mRNA gene expression in the colonic tissue (C)
Body weight (D) Hematocrit (E) Colon length (F) Histopathological grading of
colonic inflammation at the end of the experiment. Data are expressed as mean
± SE, n=10/group.
Figure 4.2. Decreased histological severity in AhR – /+ mice during DSS-induced
colitis. (A) H&E-staining of colons from WT (upper panel) and AhR– /+ mice (lower
panel). (B) Immunohistochemistry for epithelial cell proliferative index (PCNA) in
sections of the colonic tissue of WT (upper panel) and AhR– /+ mice (lower panel).
Figure 4. 3. The expression of pro-inflammatory cytokines and macrophage
marker are reduced in AhR – /+ mice during colitis. (A) TNFα gene expression, (B)
TNFα protein level, (C) F4/80 gene expression (D) MCP1 gene expression, (E)
IL10 gene expression and (F) IL10 protein level in colonic tissue. Data are
expressed as mean ± SE, n=10 / group
Figure 4. 4. Differential expression of master regulators for Treg and Th17 cells
in the colon of WT and AhR – /+ mice. Increased expression of (A) FoxP3 mRNA
gene expression and attenuated gene expression of (B) RORγ and (C) IL17 with
a low level of (D) IL17 protein expression in AhR – /+ mice treated with DSS. Data
are expressed as mean ± SE, n=10/group.
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Figure 4.5. Proinflammatory adipokines are decreased in AhR – /+ mice treated
with DSS. The pro-inflammatory adipokines (A) Angiotensinogen (B) ACE, (C)
AT1a receptor, (D) Osteopontin gene expression were significantly lower in AhR
heterozygous mice during colitis. Data are expressed as mean ± SE, n=10/group.
(E) Fluorescence immunohistochemistry for angiotensin II (green) and AT1aR
(red) in AhR – /+ and WT mice treated with DSS. (a), (b) show dual staining
Figure 4.6. Adiponectin is negatively regulated during colitis only in WT mice and
not in the AhR – /+ mice. (A) Adiponectin gene expression in WT mice treated with
DSS was significantly lower compared to AhR – /+ mice. (B) Decreased TCadherin receptor expression in WT mice with colitis. (C) and (D) Decreased
adiponectin receptors in the context of low adiponectin expression may further
impair this adipokine signaling pathway. (E) Increased gene expression of
chaperone protein ERP44 relative to its partner, endoplasmic reticulum
oxidoreductin (ERO) can block the secretion of adiponectin in WT mice with
colitis. Data are expressed as mean ± SE, n=10/group.
Figure 4.7. Reduced macrophage recruitment during DSS colitis in the AhR – /+
mice. Fluorescent immunohistochemistry showing macrophage-restricted protein
- F4/80 expression in colonic tissue of AhR-/+ mice with colitis. (A) Macrophagerestricted protein-F4/80 (green) in control groups, (B) Macrophage-restricted
protein-F4/80 (green) in DSS-treated mice groups.
Figure 4.8. AhR activation in patients with IBD. (A) CYP1A1 mRNA gene
expression level is increased in IBD patients compared with control. (B) IL8
mRNA gene expression increases during the inflammatory process in IBD
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patients. Control n=15, IBD n=25. Data are expressed as median. (C, D)
Fluorescent Immunohistochemistry staining of the AhR in a control patient (C)
versus a patient with Crohn’s disease (D). Representative images are shown of
biopsies obtained from a control subject (C) and from a patient with Crohn’s
disease (D). Red staining indicates binding of the antibody to human AhR. All
samples were counterstained with DAPI (blue) to visualize nuclei. Magnification
is 20X. E - Enterocytes and LP- Lamina Propria.
Supplemental Figure 4. 9. Epithelial cellular stress is decreased in AhR – /+ mice
exposed to DSS. Decreased mRNA gene expression of endoplasmic reticulum
stress response proteins (BIP, XBP1) and related pro-apoptotic factors (CHOP,
Casp12). Data are expressed as mean ± SE, n=10/ group
Supplemental Figure 4.10. Decreased expression of Secretory leukoprotease
inhibitor (SLPi) in WT compared to AhR – /+ mice exposed to DSS, consistent with
reduced inflammation in the AhR heterozygote mice during colitis. mRNA gene
expression in colonic tissue. Data are expressed as mean ± SE, n=10/group.
Supplemental Figure 11. Decreased renin angiotensin system (RAS)
components in AhR – /+ mice correlates with a better outcome of DSS-induced
colitis in AhR heterozygote mice. Fluorescent immunohistochemistry shows
expression of ACE (red – upper panels), Angiotensin (green – lower panels) and
their co-localization (middle panels) in the colonic tissues of mice treated with
water (left panels) compared with DSS treatment (right panels).
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Figure 4.1 The severity of DSS-induced colitis is attenuated in AhR – /+ mice
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Figure 4.2 Decreased histological severity in AhR – /+ mice during DSS-induced
colitis
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Figure 4.3 The expression of pro-inflammatory cytokines and macrophage
marker are reduced in AhR – /+ mice during colitis
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Figure 4.4 Differential expression of master regulators for Treg and Th17 cells in
the colon of WT and AhR – /+ mice
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Figure 4.5 Proinflammatory adipokines are decreased in AhR – /+ mice treated
with DSS
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Figure 4.6 Adiponectin is negatively regulated during colitis only in WT mice and
not in the AhR – /+ mice
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Figure 4.7 Reduced macrophage recruitment during DSS colitis in the AhR – /+
mice
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Figure 4.8 AhR activation in patients with IBD
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Supplemental Figure 4.9 Epithelial cellular stress is decreased in AhR – /+ mice
exposed to DSS
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Supplemental Figure 4.10 Decreased expression of Secretory leukoprotease
inhibitor (SLPi) in WT compared to AhR – /+ mice exposed to DSS, consistent
with reduced inflammation in the AhR heterozygote mice during colitis
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Supplemental Figure 4.11 Decreased renin angiotensin system (RAS)
components in AhR – /+ mice correlates with a better outcome of DSS-induced
colitis in AhR heterozygote mice
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Chapter 5.
Conclusions:
Inflammatory Bowel Diseases are heterogeneous chronic relapsing
conditions divided into two main phenotypes: Crohn's Disease and Ulcerative
colitis. 1.Each category is further sub-typed according to established clinical
criteria that take in consideration disease location, age at diagnosis and specific
complications14. Nevertheless, this approach does not offer insight into the
immune mechanisms that contribute to a unique phenotype. Moreover, it
assumes that Inflammatory Bowel Diseases are a continuum development of a
common pathologic process and expected to yield similar results to treatment.
Evidence from experimental models of Inflammatory Bowel Diseases is
somewhat deceptive since knockouts of specific proinflammatory cytokines
appear to cure the disease in spite of the clinical results in patients. A classic
example is tumor necrosis factor alpha (TNFα). TNFα-KO mice are resistant to
TNBS-hapten induced colitis and overexpression of a TNFα transgene results in
severe colitis211. Clinical trials in IBD patients indicate that only 30% of patients
on anti-TNF therapy achieve long-term remission212. We have investigated the
mRNA expression of TNFα in mucosal biopsies from healthy volunteers and
patients with Inflammatory Bowel Diseases213. In both groups, we noted a
significant variation in expression and concluded that alone, this cytokine will not
be informative. A similar trend was noted for other molecular targets relevant to
the mucosal immune system. Genetic variations, unique microflora as well as
redundant inflammatory pathways may explain the heterogeneity. On the other
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hand, the concept of "physiologic gut inflammation" allows for cytokines such as
TNFα to play both protective and pathologic roles, and its relative expression less
significant. Given the focused approach of current biologic therapies in IBD, it is
important to determine the immune phenotype of these patients. Instead of
pursuing isolated molecular targets, we investigated patterns of expression, for
multiple factors, relevant to the innate immune function of the gut. Principal
component analysis of the relative expression of RelA, A20, pIgR, TNF, and IL-8
in IBD (Crohn's type) allowed us to stratify patients into three immune
phenotypes. Furthermore, they were correlated with treatment outcome and
provided a "molecular signature" for Crohn's Disease. RelA, A20, pIgR, TNF
mainly defined the first component of this statistical analysis (PC1), while the
second one, (PC2) was weighted toward TNF, and IL-8. A high PC1 score and
low PC2 characterized healthy volunteers and Crohn's Disease patients with very
mild disease. This suggests that RelA, A20, and pIgR fulfill a protective role in
the gut mucosa while TNFα and IL-8 are mainly pathogenic. Although NF-kB
regulates the production of inflammatory cytokines, recent studies confirmed its
importance for the integrity of epithelial barrier15 . Absence of ubiquitin-modifying
enzyme A20 leads to excessive NF-kB stimulation downstream of TNFα and TLR
signaling28. Thus, it provides a negative feedback, and likely contributes to the
"physiologic inflammation". Another important intestinal epithelial NF-kB target is
pIgR. Its baso-apical traffic ensures the continuous IgA transport in the gut lumen
and thus contributes to the mucosal immune homeostasis214. The subgroup of
patients with the lowest pIgR expression (lowest PC1) had almost absent IgA
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transport. Interestingly the IgA was deposited in the lamina propria similar to
patients with IgA nephropathy. They had higher than normal serum IgA as well.
One explanation for the latter finding is that increased lamina propria IgA is taken
up into the circulation. On the other hand, low pIgR expression may lower the
epithelial defensive capacity and allow bacterial translocation, which in turn
stimulates the IgA response to luminal bacteria. This conclusion is supported by
evidence of barrier defects in pIgR knockout mice 23 as well as increased
circulating antibodies to luminal bacteria in IBD patients215-216. Interestingly these
patients had low NF-kB, TNFα and IL8 expression consistent with an immunodeficient status in the absence of immunomodulatory drugs. Clinically these
patients were refractory to medical therapy. Since their previous treatment,
regimens were largely immunosuppressive we can argue that this group would
be candidate for immunostimulatory regimens such as GM-CSF. Our findings are
in agreement with prior evidence of innate immune deficiency in Crohn's Disease
patients217-218. Similar to our patients they had a blunted IL8 response. The most
common genetic mutation in CD patients involves NOD2 gene. Current studies
link this intracellular bacterial sensor to protective NF-kB signaling in gut
epithelium as well as mucosal defensin production by Paneth cells219.
Nevertheless, we did not find an association with our patient subsets. Crohn's
Disease patients with high C reactive protein levels tend to be more responsive
to anti-TNF therapy220. Our subset of patients with high PC2 scores (higher TNF,
IL8) matched these characteristics. They tended to be earlier in the disease
process as well. It should be noted that TNFα and IL8 expression was elevated in
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areas unaffected by disease and were not simply markers of acute inflammation.
The identification of signature biomarkers of Crohn's Disease has several
implications: 1) subset 1(↑PC1↓PC2) may not require top-down therapy and/or
do well with drug holidays; 2) subset 2 (↓PC1↓PC2) should be the object of
immunostimulatory therapies and definitely avoid combinations of
immmunosupressives; 3) subset 3 (↑PC2) can benefit early top-down,
combination therapy. Future prospective studies will investigate whether early
top-down therapy could switch subset 3 to subset 1 since the latter group is more
likely to maintain remission in the absence of medical treatment. Furthermore,
principal analysis of these signature biomarkers should be evaluated in various
existing models of IBD and provide immune-phenotype specific insight for
various potential treatments. In light of association between oral and intestinal
inflammation, we are investigating the usefulness of oral sampling in lieu of the
more invasive gut biopsies.
In light of our findings we propose that activation of downstream of extra
and intracellular microbial sensors induces/activates NF-kB and its target genes
pIgR, IL8 and TNFα. Activation of NF-kB is limited by A20 mediated inhibition
and thus prevents ongoing inflammation. Increased pIgR expression assures
adequate IgA transport with an important role in tolerance toward commensals
and possibly neutralization of the proinflammatory chemokine IL8. The severe
IBD phenotype observed in the subset of patient with low pIgR expression
reflects an immune deficiency of the gut epithelium. These patients have low NFkB relA levels, which may theoretically be linked to ER stress response and
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defective autophagy mechanisms. Ongoing anti-TNF treatment of these patients
may aggravate the immune barrier dysfunction and favor a Th17 response to
invading bacteria.
Crohn’s disease patients develop transmural inflammation of the
gastrointestinal tract, which may lead to complications such as strictures and
perforations. Often times, there is significant hypertrophy and inflammation within
the surrounding mesenteric fat. Recent advances in metabolic and
cardiovascular diseases have led to a paradigm shift in which adipose tissue has
been upgraded from an energy depot to a source of immunomodulatory
cytokines (adipokines). In his original description of the disease, Burril Crohn
described the characteristic mesenteric fat change100. Although widely
recognized, the relevance of this fat hypertrophy, referred to as “creeping fat”, is
unknown, and has received little research attention. Accumulation of mesenteric
fat, appears to be specific for Crohn’s disease, and occurs from the onset of
disease37. Fat wrapping has been defined as fat hypertrophy extending from the
mesenteric attachment with > 50% coverage of the intestinal surface101. It occurs
in both the small and large bowel, and correlates with transmural inflammation,
ulceration, stricture formation, increased mesenteric wall thickness, and
decreased internal bowel diameter101. Fat wrapping and mural thickening is
associated with mucosal ulceration in 86% of patients102 and with strictures in
46%102. Importantly it was noted in 100% of patients undergoing resection, and
correlated with the degree of acute and chronic inflammation103. Adiponectin, a
fat derived hormone/cytokine is involved in cell energy regulation, glucose
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metabolism and modulation of immune responses221. We evaluated the role of
adiponectin in a DSS model of colitis. Adiponectin or LacZ (control gene) was
overexpressed using an adenoviral construct43. The adiponectin treatment group
has a significantly better outcome as assessed by clinical and histologic criteria.
We chose an innate immunity mouse model of IBD since adiponectin has
structural and functional similarities to complement. The first evidence for a
protective role came from the Nishihara group42. They demonstrated that
adiponectin treatment protects adiponectin KO mice from DSS colitis.
Interestingly no benefit was noted in TNBS colitis. Since the latter model is more
dependent on T cells, one may speculate that adiponectin has greater influence
on innate immunity. This is also supported by the fact that T cells from either wild
type of adiponectin KO mice produce similar amounts of IL-6, IL-17, TNF-α and
IFNγ upon stimulation with anti CD3/CD28 222. In vitro studies revealed that
adiponectin suppressed expression of IL-8 in the human HT-29 epithelial cell line
42

. Surprisingly, others223 found that the adiponectin promotes and potentiates IL-

8 in the same cell line. Nevertheless this activity was elicited by globular
adiponectin at doses between 1 and 5μg/ml. Adiponectin circulates mostly as
HMW
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at similar concentrations and it is unlikely that globular form will be

generated in vivo at the same levels. We prospectively evaluated adiponectin
levels in two cohorts of Crohn's Disease patients and healthy volunteers
respectively. There was no difference between total adiponectin but we
detected significantly lower values in the HMW fraction224. The differences
between controls and IBD patients were not related to common adiponectin SNP
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mutations. Nevertheless, when Crohn’s Disease patients were analyzed, a third
of those with A>G 11426 in the promoter region had fistulizing or stricturing
disease while less than 15% had this phenotype in the absence of mutation. This
mutation lies within a PPARγ response element and may be responsible for the
induced rather than the constitutive adiponectin level. In addition, inflammatory
cytokines and cellular stress can modulate HMW secretion225. Based on our
studies and prior evidence we believe that TNFα, angiotensin and osteopontin
play an important role. Altered receptor expression can further modulate the
effects of adiponectin. Overall, no significant changes in adiponectin receptors
were seen in our mouse model. This may be because we analyzed the entire
colonic specimen rather specific cell fraction. Using in-vitro bone marrow derived
dendritic cells, we determined that LPS downregulated AdipoR1 and AdipoR2.
This may represent a state of adiponectin resistance that can be reversed by
PPARγ and retinoic acid agonists. We also correlated serum HMW adiponectin
and colonic adiponectin receptors expression with specific IBD subgroups.
Crohn's Disease patients in subsets 2(↓PC1↓PC2) and 3 (↑PC2) had lower
circulating HMW adiponectin and intestinal receptor mRNA expression.
In sharp contrast to our findings, Fantuzzi et al, showed that adiponectin
KO mice were protected from DSS and TNBS colitis, and adiponectin treatment
induces inflammation41. In addition, colonic explants from treated mice released
more IL-6. Differences in adiponectin KO mice have been invoked since only the
former group showed high basal TNF-α production and increased susceptibility to
LPS. Several recent studies confirm that adiponectin effectively blocks LPS
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induced release of pro-inflammatory cytokines and thus support an antiinflammatory role138,226-228. Moreover, when the latter group investigated the
outcome of colitis in IL-10 KO and adiponectin/IL-10 double KO no differences
were seen 222. It was concluded that adiponectin does not play a role in this
colitis model. In accordance with our preliminary experiments, and published
data 134,229 we believe that IL-10 production is paramount for the antiinflammatory role of adiponectin in colitis. Therefore, the results seen in IL-10 KO
mice are expected. Furthermore, if adiponectin promotes inflammation the
double KO (adiponectin/IL-10) mice should have had increased morbidity and
mortality. Adiponectin induced IL-10 may thus promote alternative activation of
macrophages and promote resolution of chronic inflammation. Adipose tissue
macrophages from lean mice express many genes characteristic of M2
(alternatively activated phenotype) macrophages230, including Ym1, arginase 1,
and IL-10. Diet-induced obesity decreases expression of these genes while
increasing expression of those encoding TNF-α and Nos2 (nitric oxide synthase)
that are characteristic of M1 (classically activated) macrophages231. Furthermore,
AMPK, the kinase that translates adiponectin signaling, suppresses
proinflammatory responses and promotes macrophage polarization to an antiinflammatory, M2 functional phenotype 232. Our findings in the DSS model of
colitis were consistent with reduced gut macrophage infiltration and increased
markers of M2 polarization. The in vivo events leading to IL10 secretion are not
established. Upregulation of adiponectin receptors on antigen presenting cells,
as seen in our in vitro study, or increased phagocytosis of apoptotic bodies
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through specific interactions between adiponectin and thrombospondin are
attractive hypotheses. Osmotin a plant derived adiponectin receptor agonist 233
ameliorated DSS colitis and promoted IL10 secretion. Since Osmotin is
structurally different, a direct effect rather than interaction with other inflammatory
mediators is suggested. Angiotensin acts as a pro-inflammatory cytokine and
promotes development of colitis 81,234. Both gut epithelium and surrounding
mesenteric fat can convert angiotensinogen to active angiotensin. We have
consistently seen a negative correlation between angiotensin/angiotensin
receptor 1 and adiponectin levels. Thus, modulation of fat derived adipokines by
adiponectin contributes to the anti-inflammatory milieu during colitis.
Environmental factors play an important role in Inflammatory Bowel
Diseases235. The strongest association has been seen with cigarette smoke
exposure 236-237. Cigarette smoke contains a mixture of dioxin-like compounds,
which activate the aryl hydrocarbon receptor (AhR) pathway. In its inactive state,
the AHR exists as a multiprotein complex. Following agonist binding, the AHR
translocates to the nucleus, dimerizes with its DNA binding partner ARNT and
binds specific DNA sequences (DREs). AHR activation by endogenous
agonist(s) is likely transient and physiological. Activation by synthetic long-lived
exogenous agonists, as TCDD is inappropriately sustained and hence,
pathophysiological. Candidate endogenous AHR agonists include indole and
tryptophan metabolites 89,238. Indole is produced from tryptophan by the
commensal bacteria and inhibits NF-κB signaling, tight-junction resistance and
expression of inflammatory cytokines in intestinal cells239. We have found that
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AHR expression appears to be largely restricted to enterocytes in human patients
240

. Thus, we speculate that the normal, physiological role of the AHR within the

intestine is to sense the presence of the bacterially generated AHR agonists and
regulate physiological inflammatory responses. Our experiments in AhR -/-,
heterozygote and wild type mice yielded different phenotypes240. The AhR
heterozygote was protected from colonic inflammation. Both AhR -/- and wild type
mice had severe colitis but the former exhibited increased mortality. We
proposed that complete absence of AhR may alter gut permeability and promote
inflammation. The results in AhR -/- were consistent with observations that these
mice have a heightened response to LPS stimulation. In comparison to wild type
mice, the heterozygote mice had a shift toward the Treg phenotype. Specifically,
we observed an increased intestinal FoxP3 expression at the expense of RORγ.
Thus, AhR ligands (endogenous and dietary) can alter the Treg/Th17 balance241.
Consistent with this polarization we noted increased IL10 production and
decreased IL17 and TNFα in the colon of AhR heterozygote mice. Furthermore
these mice had lower levels of MCP-1 and colonic macrophages. The observed
effects were related to the AhR level of expression. Similar conclusions can be
draw from our analysis of Crohn's Disease and healthy volunteers. We have
assessed AhR activation by determining the expression of its nuclear target
CypA1. In normal subjects, there was minimal AhR activation restricted to the
epithelial layer. This likely reflects the AhR role in gut permeability. Treatment of
the human epithelial colonic line CaCO2 with an AhR antagonist significantly
decreased the transepithelial electrical resistance while the long acting agonist,
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TCDD restored it. Analysis of intestinal biopsies from IBD-Crohn's Disease
patients have showed decreased epithelial expression and significant
upregulation in lamina propria mononuclear cells. The upregulation of AhR
expression correlated with an AhR responsive inflammatory cytokine, IL8.
Although CypA1 was used as a read-out of AhR activation, interactions with NFKB (RelA and RelB) through a non-canonical pathway are likely important90. It is
generally accepted that AhR and NF-kB negatively regulate each other.
Therefore it is conceivable that increased epithelial AhR expression reduces NFkB and thus alters gut permeability. Since AhR -/-, mice have developmental
defects we explored the effects of pharmacological blockade on DSS colitis in
wild type mice. A similar outcome was noted. On the other hand, TCDD, a long
acting agonist protects mice from DSS colitis. Preliminary studies in our
laboratory confirmed these findings in mild (1.5% DSS) but not severe forms of
colitis (3.5% DSS).
We have previously shown that AhR agonists (TCDD, PCB77) promote
obesity and adipose tissue inflammation84. These lipophilic compounds are
widely distributed in the environment, and preferentially accumulate into the
visceral fat. Furthermore, we showed that PCB77 treatment promotes
perivascular inflammation and intraabdominal ectopic fat deposition in a mouse
model of aortic aneurysm (manuscript submitted). Therefore, we investigated the
profile of anti-inflammatory (adiponectin) and pro-inflammatory (angiotensin)
during DSS colitis in mice with low (AhR-/+) and normal AhR expression. AhR
heterozygote mice (AhR-/+) exhibited a significant downregulation of angiotensin
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precursor, angiotensin receptor AT1a and angiotensin converting enzyme (ACE)
correlated with a positive clinical outcome. Furthermore, serum and tissue levels
of adiponectin were elevated. The link between AhR, adipokines, inflammation
and obesity is of high relevance since an important number of IBD patients are
either obese or at risk of metabolic syndrome. Recent associations between IBD
(Crohn's Disease and Ulcerative Colitis) and BMI (body mass index) could reflect
the effect of AhR on disease phenotype 36,242.
In summary, we provide evidence of unique immune phenotypes in IBD
with relevance for clinical practice. Furthermore, the signature biomarkers for
Crohn's Disease may serve as a guide to patient selection in clinical trials and
development of relevant animal models. Our current studies link adipose tissue
derived cytokines with the xenobiotic pathway, and offers a framework to further
evaluate the role of environmental cues in IBD development. We propose a
disease model whereby genetic and environmental factors (AhR ligands) alter
gut barrier by acting on targets such as NF-kB and pIgR. This leads to bacterial
translocation with specific patterns of inflammation related to the patient's
immune phenotype (biomarker subset). Increased visceral adiposity (diet, AhR
mediated) and accumulation of lipophilic AhR ligands induces a second wave of
inflammatory mediators. Low adiponectin and activation of the renin angiotensin
system within the gut and surrounding adipose tissue are expected to promote
an inflammatory milieu. Ultimately, these events can promote M1 macrophage
and Th1/Th17 polarization responsible for the chronic relapsing course of IBD.
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Future Directions
Investigation of NF-kB related targets relevant for innate mucosal
immunity, allowed us to identify the pIgR/IgA system as a novel pathway in
patients with Inflammatory Bowel Diseases. More importantly, it points to the fact
that a pathway approach is likely to yield results in the quest for disease
biomarkers. The current five-biomarker set will be expanded to include
adipokines, adipokine receptors and components of the aryl hydrocarbon
pathway. Selection of specific targets will be guided by in vitro studies. I am
particularly interested in regulation of TLR signaling by adiponectin and
downstream interactions with canonical and alternative NF-kB pathways.
Ultimately, the utility of these biomarkers have to be tested in prospective clinical
trials. Inflammatory Bowel Diseases naïve to immunomodulatory therapies will be
randomized to treatment based on the biomarker subsets. The clinical response
and mucosal healing will be assessed and correlated with subset allocation.
Another important question that may be answered is whether these subsets are
stable or they can be altered by successful immune therapies. These finding may
have significant importance on early choice of treatments. Analysis of biomarker
expression in the gut mucosa requires an invasive endoscopic procedure. On the
other hand sampling of oral mucosa would be easily performed. Therefore, we
would like to investigate the correlation of proposed gene targets in the gut and
oral mucosa and thus offer a better modality of immune-phenotyping the IBD
patients.
A significant number of IBD patients are overweight. Our results are in line
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with studies that link adiponectin to innate immunity response and macrophage
function. We propose that signaling downstream of adiponectin receptors alter
the balance between M1 (classical) and M2 (alternative) macrophages. Targeted
deletion of macrophage adiponectin receptors, and/or chimeric mouse models
using macrophage transfer from receptor KO mice will be investigated in acute
and chronic models of colitis. Adiponectin replacement is not considered a
feasible treatment modality. Alternative options include: 1) synthetic or natural
agonists; 2) increased receptor expression. We have discovered that the plant
agonist Osmotin can have protective effects during colitis. Further studies will
test its value in the context of impaired adiponectin activity: 1) selective
adiponectin receptor deficiency; 2) adiponectin deficiency (KO mouse);3)
acquired adiponectin deficiency through diet induced obesity.
Although the role of environment in Inflammatory Bowel Diseases is
widely accepted, until recently, no specific pathway was identified. Our study
identified for the first time that the aryl hydrocarbon might play a role in the
development of IBD. The main target of the AhR signaling in both human and
experimental IBD has not been elucidated. We will investigate the consequences
of AhR deletion in gut epithelial cells as immune cells. Moreover, T cell transfer
from mouse donor exposed to individual AhR ligands (agonists and antagonists)
as well as complex mixtures (cigarette smoke) will allow dissection of more "reallife" scenarios. We are hopeful that our research endeavors will create a better
understanding of the link between environment, metabolism and immunity.
Copyright @ Razvan I Arsenescu
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